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ABSTRACT OF THE DISSERTATION
Biophysical studies of the intracellular domains of the EGFR family of Receptor Tyrosine
Kinases
by
Kwabena Amofa Nketia Sarpong
Doctor of Philosophy in Biology and Biomedical Sciences
Biochemistry
Washington University in St. Louis, 2017
Professor Ron Bose, Chair
The epidermal growth factor receptor and its three orthologues, HER2, HER3 and HER4 have
been the subject of intensive basic, clinical and translational research due to their involvement in
cancers. These proteins are part of elaborate networks that interact with a myriad of other
molecules to effect diverse signaling pathways and affect cellular processes such as migration,
apoptosis, cell differentiation and so on. In addition to the formation of preformed dimers, it is
well established that ligand engagement leads to receptor dimerization in all family members,
except HER2. In the past decade, it has been shown that their intracellular domains dimerize in
xi

an asymmetric fashion where the C-lobe of the donor kinase interacts extensively with the Nlobe of the receiver kinase. This structural model is critical for activation of the receiver kinase
and subsequent phosphorylation of the C-terminal tail. While the structures of the different
domains have been solved, minimum structural and biophysical studies have been performed on
the C-terminal tails. In this thesis, we use multiple approaches to characterize the C-terminal tails
of EGFR and HER3, and show that they are intrinsically disordered regions of these receptors.
We also developed a strategy that has been employed to site-specifically fluorophore-label the
EGFR kinase domain, and would serve as a biological probe to directly measure EGFR kinase
domain dimerization on lipid surfaces.

xii

Chapter 1: Introduction
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1.1 EGFR Receptor Tyrosine kinases, an overview
The isolation of the epidermal growth factor by Stanley Cohen in the 1950s (1) and its
significance in physiology led to the identification of the epidermal growth factor receptor,
EGFR, HER or ERBB1 (2). Since then, the EGFR family has grown to include HER2 or
ERBB2, HER3 or ERBB3 and HER4 or ERBB4 (3). These family of receptor tyrosine kinases
(RTKs) play significant roles in the normal functioning of the cell. Cellular processes that these
RTKs regulate include cell migration, proliferation and differentiation, cell survival and
metabolism, and cell-cycle control. All four family members share a very similar molecular and
structural architecture; a large ectodomain, that binds of ligand, a single alpha helical
transmembrane domain, and an intracellular cytoplasmic domain that contains the
juxtamembrane segment, the kinase domain and an intrinsically disordered C-terminal tail region
as shown in Figure 1.1 (4-7). Except HER2 which is constitutively active and does not have a
cognate ligand, the other three members are activated by ligands (epidermal growth factor,
transforming growth factor, heregulin, amphiregulin and heparin-binding epidermal growth
factor) (8). HER3 on the other hand has little to no kinase activity and studies have shown that
HER3 assumes the donor kinase position when in a heterodimeric pair (4,9). Following
dimerization of the extracellular domains, their intracellular cytoplasmic domains dimerize in an
asymmetric fashion and activates the receiver kinase. This engages the unstructured C-terminal
tail and becomes phosphorylated at various tyrosine residues, providing docking sites for Src
homology 2 or phosphotyrosine-binding signaling molecules to interact (Figure 1.1) (10). The
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result is the recruitment of other adaptor proteins that signal via different pathways (11-14).

Figure 1.1. Structural architecture and mechanism of activation of the EGFR family of
Receptor Tyrosine Kinases. This figure is adapted from Zahnow, C.A., 2006 (10)

1.2 Role and significance of EGFR family in cancer
EGFR involvement in cancer surfaced in the 1980s when the erythroblastosis tumor virus was
shown to encode an abnormal form of EGFR. The EGFR family of receptor tyrosine kinases
have been implicated in several solid tumors (11). These cancers have often been overexpression
of the receptors, gene amplification, autocrine loop activation and the presence of activating
somatic mutations in the EGFR family (15-19). It has been widely known that the HER2-HER3
signaling is the most potent signaling pair (20), especially in HER2-amplified breast cancers
where HER3 expression is a requirement for the growth of these cancers. A similar consequence
is seen in patients with non-small cell lung cancers caused by an activating mutation in EGFR,
3

where studies have shown that suppression of HER3 signaling results in growth suppression (21,
22). HER3 is now an actively pursued drug target since it provides acquired resistance to
therapeutics by activating alternative signaling pathways (23). HER3 achieves this by increasing
outputs in processes such as transcription, translation, phosphorylation and the use of other
redundant mechanisms which are downstream of its signaling output. Somatic mutations in
HER3 have recently been published and various groups are actively pursuing the functional
significance of these mutations (18, 24-26). HER4, on the other hand has not been shown to have
important roles in cancer, though some studies have reported its involvement in melanoma (27).
Currently, there are FDA-approved small molecule tyrosine kinase inhibitors such as lapatinib
and antibody-based therapeutics such as trastuzumab and pertuzumab that target EGFR and
HER2-driven cancers (28-30).
1.3 Structural analysis of the kinase domain of the EGFR family
The structural organization of EGFR and its three orthologues (HER2, HER3 and HER4) is
strikingly similar; they all possess a large extracellular domain that binds to ligand, a single
alpha-helical transmembrane domain and an intracellular cytoplasmic domain that contains the
kinase domain and the intrinsically disordered C-terminal tail (4-7). The extracellular domain is
organized into 4 subdomains. While subdomains I and III are rich in leucine repeat motifs,
subdomains II and IV contain C-C disulfide-rich bonds. In the absence of ligand, EGFR, HER3
and Her4 receptors exist in a closed, tethered conformation that is mediated by interactions
between domains II and IV. EGF (or other cognate ligands) binding leads to an alteration in the
structure of the extracellular domain to create a ligand-binding pocket and the protrusion of a
dimerization arm (from subdomain II). Homo- and heterodimerization is facilitated by
interactions with the dimerization arm (31). HER2 does not require ligand binding to achieve an
4

active conformation and its extracellular domain is poised in a fixed, activated state even when
monomeric, rendering HER2 permanently available for dimerization (32). There are dimer
contacts in the extracellular and intracellular regions as well as the transmembrane helix, though
not coupled together (33). The kinase domain consists of the N-terminal and C-terminal lobes.
Several lines of evidence show that the kinase domain dimerizes in an asymmetric fashion;
where the C-lobe of the donor kinase makes extensive contacts with the N-lobe of the receiver
kinase. In this model, (figure 1.2) the receiver kinase becomes activated and phosphorylates
tyrosine residues in the C-terminal tail, which serve as docking sites for phosphotyrosine-binding
proteins and SH2 domains (4). The activation process is sequential and dependent on the
enzymatic kinase activity of the receptor (34). Other critical regions in the kinase domain
include the activation loop and the C helix, both of which adopt different conformations when
in an active or inactive state (35). The formation of the asymmetric dimer means that specific
mutations at the interface can compromise the catalytic activity of the kinase (4, 36).

Figure 1.2. Model of the EGFR asymmetric kinase domain dimer. This figure is adapted
from Zhang et. al, 2006 (4)

5

1.4 Inhibition of the kinase domain by small molecules and Mig6
Since the discovery of their involvement in cancer, a variety of therapeutic strategies have been
developed to target EGFR family of proteins-driven tumors. This has been achieved by using
monoclonal antibodies such as pertuzumab, trastuzumab and others that bind to the ectodomain
and interfere with signaling. These antibodies are either used singly or in combination, where
their proposed mechanism of action is bind to subdomain II or IV resulting in the inhibition of
dimerization and blocking of ligand-dependent and ligand-independent signaling (37). Recently,
alternative approaches have been investigated and resulted in the use of ATP-competitive small
molecules to inhibit the kinase domain (30). While some of these kinase domain inhibitors
possess a reversible mode of action, others such as neratinib attaches irreversibly to the cysteine
residue close to the ATP binding domain and results in the complete shutdown of the kinase
activity of the receptor (28). Although enormous success has been achieved by targeting the
extracellular and kinase domains, the emergence of drug resistance has necessitated the
development of new targets and better therapies for these EGFR-driven cancers (38). The
formation of an asymmetric dimer is critical for activation of the kinase and downstream
signaling. This dimer interface presents a crucial target that can be exploited for development of
drug candidates to inhibit EGFR signaling. Indeed, there is an endogenous protein, Mig6
(Mitogen-induced gene 6) that is known to bind to the kinase domain and inhibit its activity.
Structure-based methods have shown that Mig6 binds to the distal surface of the C-lobe of the
kinase domain and thus prevents the formation of an asymmetric dimer (39). The Bose lab and
other research groups are actively pursuing the use of the Mig6 peptide (and its other mutants) to
inhibit dimerization and block signaling (unpublished data).
1.5 Regulation of EGFR signaling by the C-terminal tail
6

The intracellular domain of EGFR (and its three orthologues) consist of the membrane proximal
juxtamembrane segment, the kinase domain and a C-terminal tail that contains more than 200
residues. Composite analysis has shown a <25% sequence similarity among the four EGFR Cterminal tails. Upon dimerization and activation, the C-terminal tail interacts with the active site
of the kinase domain and results in the phosphorylation of the tyrosine residues (11). The
phosphorylated tail serves as a docking site for binding by phosphotyrosine binding proteins and
other proteins that contain SH2 domains (40). In addition, phosphatases can dephosphorylate the
C-terminal tail (41, 42). This cycle of events compels the C-terminal tail to adopt a variety of
conformations that allows it to interact efficiently with its different partners under various
conditions. It wasn’t until recently that structural and biophysical approaches begun to shed light
on our understanding of the C-terminal tail (43-45). Experimental and in silico approaches have
shown that the C-terminal tail of EGFR and HER3 are intrinsically disordered, and possess a
larger apparent molecular size compared to a globular protein of similar molecular weight (45).
Crystal structures containing residues 982-1022 of the C-terminal tail of EGFR have suggested a
negative inhibitory role for the C-terminal tail. In this model, the proximal residues of the Cterminal tail form an alpha helix (residues 997-1001) that stabilizes the inactive dimer, while the
acidic residues (Electrostatic hook, residues 1003-1014) and distal residues (1015-1022) that
form a beta strand prevents the formation of the juxtamembrane latch necessary for activation
(46). This finding is buttressed by another study where the authors identified residues 982-1054
in the proximal region of the C-terminal tail that inhibit the formation of an asymmetric dimer
(47)
1.6 Protein intrinsic disorder and role in diseases
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Intrinsically disordered proteins (IDPs) are regions or domains that do not have stable secondary
or tertiary structures. Nonetheless, these regions maintain the ability to function in cellular
processes including regulation of transcription, signaling, protein-protein interactions, cell life
cycle events etc. They perform these roles due to their ability to adopt different conformations
under different conditions and due to their structural flexibility (48-55). This results in IDPs
having to fold and assume different conformations when interacting with different partners.
Misfolding of these regions ultimately leads to the formation of unwanted aggregates and
complexes which do not possess the structural and functional integrities to undertake their roles
thereof. The proteomes of eukaryotes are replete with intrinsically disordered regions, where
most of these proteins contain long stretches of disordered regions or the whole protein is almost
completely disordered (56). Using PONDR VL-XT disorder predictor algorithm to analyze
protein datasets, it has been suggested that there is a strong correlation between protein intrinsic
disorder and their roles in signaling and cancer (57). Most importantly, in silico and experimental
data have revealed many protein kinases contain intrinsically disordered regions, which facilitate
their interactions with other proteins and enhance their signaling outputs (58).
1.7 Biophysical approaches for studying intrinsically disordered proteins
Though intrinsically disordered proteins might be accorded unstructured properties in protein
chemistry, their functional properties provide enormous suggestion that their structural
organization is intimately related to the cellular processes they are involved in. Traditional and
classical methods such as Nuclear Magnetic Resonance and X-ray Crystallography were mainly
developed to study proteins that form stable structures. Due to their structural and other inherent
physical properties, it is often very difficult to obtain high concentrations or representative
crystal structures of IDPs to enable their study using these traditional methods (51, 53). In the
8

past few years, there have been considerable efforts to develop methods to study the behavior of
IDPs. Scattering approaches such as Dynamic and Light Scattering, Small Angle X-ray
Scattering

and

Small

Angle

Neutron

Scattering

in

combination

with

Analytical

ultracentrifugation and Size Exclusion Chromatography have been used extensively to assess the
size and shape of proteins (59-63). These methods can provide quantitative measurements such
as the hydrodynamic radius, radius of gyration, stoke radius on IDPs under solution conditions.
Because of their highly dynamic and flexible nature, experimental and molecular dynamics
methods have been and are still being developed to analyze the conformational behavior of IDPs.
Lastly, temperature, pH and denaturant-induced changes together with single-molecule
Fluorescence Resonance Energy Transfer and Hydrogen-Deuterium exchange with mass
spectrometry have spearheaded experimental approaches that are utilized to assess the
conformational transitions of IDPs (64-68)
1.8 Site-specific modification of proteins
Biotechnological and biochemical applications are becoming increasingly dependent on
derivatized proteins. These modified proteins provide excellent avenues for studying proteinprotein and protein-ligand interactions, folding, post-translational modifications, conformational
changes and further interrogating the functions of proteins both in vivo and in vitro. The past few
decades have seen the development of several protein engineering strategies to site-specifically
modify proteins by employing distinct chemistries and utilizing the specificities of various
enzymes (69, 70). Most commonly used chemical handles for protein modification include
fluorescent tags, chemical cross linkers, biotin, carbohydrates, nucleic acids and so on. Due to
their low abundance in the proteome, cysteines have traditionally been employed via maleimide
chemistry to label proteins (71). Other methods have exploited the reactive N-terminal amino
9

group and the -amino group of lysines to selectively attach N-hydroxysuccinimidyl esters to
proteins. In addition, chemical labeling strategies have been developed to modify tyrosine,
aspartate and glutamate residues. Chemoenzymatic approaches, on the other hand utilize a
variety of enzymes to recognize a specific engineered motif on the protein and attach a chemical
handle onto the protein.

Enzymes such as lipoic acid ligase, biotin ligase, sortase,

phosphopantetheinyltransferase among others have been employed to selectively label different
proteins (72). Such tag-mediated protein labeling approaches should (i) be fast, robust and
quantitative, (ii) be highly selective and specific, (iii) have minimum structural and functional
consequences (iv) short reaction times and (v) result in the formation of a stable, covalent bond
between the protein and the desired moiety. Although not a single method can satisfy all these
requirements, the bottlenecks associated with these labeling methods include the tolerance of the
proteins to incorporate the recognition motif and the difficulty in removing unmodified proteins
prior to their use.
1.9 The use of sortase to efficiently label proteins
Sortases are membrane-associated transpeptidases that anchor Gram-positive bacterial surface
proteins to their cell walls. Due to their significance in virulence, sortases might be considered as
strong drug targets for fighting bacterial infections. Although there are four subfamilies of
sortases (subfamily A – D), sortase A has been the prototypical member that has been studied
extensively and employed for a myriad of biophysical applications. Sortase A is more versatile
and accepts a variety of protein substrates as compared to the other family members.
Mechanistically, sortase A cleaves the threonine-Glycine bond on any protein that contains the
sortase A recognition motif, Leu-Pro-Xxx-Thr-Gly (LPXTG, where X can any amino acid,
preferably glutamate). This leads to the formation of an acyl-enzyme intermediate, which is
10

resolved by the nucleophilic attack of an oligoglycine peptide. In bacteria, the resulting
oligoglycine-protein complex becomes incorporated and displayed on the cell wall, as shown in
figure 1.3 (73-77). Because the oligoglycine and LPXTG motifs can be easily synthesized or
engineered into proteins, sortase A has been used in a variety of ways to modify any protein of
interest with different chemical handles. One important advantage in using sortase for protein
labeling is its ability to modify proteins at the C- and N-termini, and also on internal loop regions
(76, 77). Sortase-mediated reactions are known to be highly specific and result in higher yields
of the labeled protein. As a result, sortase has been utilized to label proteins in solution, in cell
lysates and on the surface of living cells.

Figure 1.3. Sortase-mediated anchoring of proteins to bacterial cell wall. Adapted from
Guimaraes et. al, 2013 (77)

1.10 Conclusion
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In conclusion, EGFR and its three orthologues have been primary targets for drug developments
for nearly four decades, because of their involvement in tumorigenesis. From a research
perspective, the common structural organization of this family of receptor tyrosine kinases
allows studying their modular domains in isolation. This helps to build a robust composite
structural picture of EGFR, and stimulate investigation of how the various domains function
together in signaling. The discovery in 2006 by the Kuriyan group, that the formation of an
asymmetric dimer by the kinase domains was needed for activation, was very critical in shaping
our understanding of the mechanistic details of EGFR signaling. The field has been fortunate to
gain detailed insights on the structural basis of activation and how specific regions such as the
juxtamembrane domain and transmembrane contribute to dimerization. Nonetheless, we still do
not have a general platform that allows the direct measurement of dimerization of the kinase
domains on lipid membranes, which would be instrumental in determining quantitative
parameters that govern EGFR kinase domain dimerization. Such studies would also allow us to
answer questions pertaining to how cancer-associated mutations affect dimerization. In addition,
the C-terminal tail of these proteins have not been extensively studied to determine its
significance in dimerization. This is in part due to the absence of enough biophysical and
structural studies on the EGFR C-terminal tails. As such, the next three chapters of this thesis
attempts to address two pertinent questions in the field: (i) what are the structural and
biophysical characteristics of EGFR and HER3 C-terminal tails and (ii) can we develop a robust
strategy to directly measure EGFR kinase domain dimerization on lipid surfaces.
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Chapter 2: Biophysical Evidence for Intrinsic disorder in the
C-terminal tail domains of the Epidermal Growth Factor Receptors

13

This chapter was adapted from:
Keppel TR*, Sarpong K*, Murray EM, Monsey J, Zhu J, Bose R. (2017) Biophysical
Evidence for Intrinsic Disorder in the C-terminal Tails of the Epidermal Growth Factor
Receptor (EGFR) and HER3 Receptor Tyrosine Kinases. J. Biol. Chem. 292, 597 – 610.
*These authors contributed equally to this work.
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2.2 ABSTRACT
The epidermal growth factor receptor (EGFR)/ErbB family of receptor tyrosine kinases include
oncogenes important in the progression of breast and other cancers, and they are targets for many
drug development strategies. Each member of the ErbB family possesses a unique, structurally
uncharacterized C-terminal tail that plays an important role in autophosphorylation and signal
propagation. To determine whether these C-terminal tails are intrinsically disordered regions, we
conducted a battery of biophysical experiments on the EGFR and HER3 tails. HDX-MS
experiments (performed by Ted Keppel, Bose lab) on the intracellular domain of EGFR, HER2
and HER3 had shown a rapid exchange behavior of the C-terminal tails compared to the kinase
domains, which is characteristic of a highly dynamic and/or frequently exchange-competent
conformational state. We expressed and purified recombinant EGFR and HER3 C-terminal tailonly constructs. Results from circular dichroism spectroscopy, size exclusion chromatography
with multiangle light scattering, dynamic light scattering, analytical ultracentrifugation, and
small angle X-ray scattering each provide evidence that the EGFR and HER3 C-terminal tails are
intrinsically disordered with extended, non-globular structure in solution. The intrinsic disorder
and extended conformation of these tails may be important for their function by increasing the
capture radius and reducing the thermodynamic barriers for binding of down- stream signaling
proteins.
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2.3 INTRODUCTION
The epidermal growth factor receptor (EGFR)/ErbB family of receptor tyrosine kinases
(RTKs) contains four member proteins: EGFR/ErbB1, HER2/ErbB2/neu, HER3/ErbB3, and
HER4/ErbB4. These RTKs carry out important signaling functions via the sequential process of
ligand binding by the extra- cellular domain, homo- or heterodimerization, activation of their
intracellular kinase domain, and recruitment of down- stream signaling proteins. These RTKs are
also important oncogenic drivers in many breast, lung, and other human cancers (78). Several
structural biology studies on the ErbB family have been published, and this has helped advance
drug development for HER2-positive breast cancer (79). Protein crystallography studies
published in 2004 showed the structure of pertuzumab bound to the extracellular domain of
HER2 and lapatinib bound to the kinase domain of EGFR (80, 81). Since that time, growing
structural biology-based understanding of how EGFR, HER2, and HER3 function at the atomic
level has dramatically reshaped our understanding of RTKs (78, 79). Despite these advances,
there is a domain in each EGFR/ErbB family protein for which little structural biology
information is available; this domain is the C-terminal tail (CTT) domain. The CTTs contain
numerous autophosphorylation sites that are essential for recruiting downstream signaling
proteins and initiating intracellular signaling (43, 82). The CTT can also contribute to
autoinhibition of the kinase domain of RTK (83). The lack of available crystallographic
information on the CTT region of EGFR/ErbB family RTKs led us to examine whether these
proteins lack a stable secondary and/or tertiary structure.

Intrinsically disordered regions (IDRs) represent an emerging area of interest in
medicine. IDRs are regions within proteins that exhibit high flexibility and may lack a secondary
or tertiary structure but are still able to carry out important biological functions (48-55).
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Algorithm prediction methods indicate that around 25–30% of eukaryotic proteins can be
categorized as having disordered regions (56). These disordered regions provide certain
advantages in protein-protein interactions, including a larger hydrodynamic radius (84, 85),
faster on- and off-rates of binding (86), high binding specificity (87), and the ability to adopt
different conformations depending on the binding partner (49,88). Correlation studies have
revealed a high propensity for disordered regions to undergo post-translational modification,
particularly phosphorylation (89). Because traditional methods, such as NMR and X-ray
crystallography, were developed to study stable protein structures, IDRs have been more difficult
to analyze because of difficulties in obtaining high concentrations or representative protein
crystals (51, 90). Correlation studies suggest a strong association between IDRs and human
cancer-associated proteins (57); therefore, identifying and analyzing IDRs in cancer-related
proteins is vital in understanding how they function.

Protein kinases demonstrate a high degree of specificity in facilitating phosphorylation;
however, many can perform such interactions with multiple substrate partners (91). An analysis
of the human kinome shows that as many as 83% of kinase genes contain IDRs, which could
facilitate these multiple interactions. RTKs are involved in more protein-protein interactions than
any other kinase group, thus potentially pointing to the involvement of IDRs in their recognition
mechanisms (58). Multisequence alignment (92) of EGFR/ErbB family RTKs shows that the
kinase domain sequences are highly conserved between all four family members. However, the
CTT regions are highly divergent between each EGFR/ErbB family member. One previous study
using circular dichroism (CD) spectroscopy indicated that the EGFR CTT is rich in -helical and
-sheet content (43), but a later study used coarse grained modeling to show many possible
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conformations of the EGFR CTT based on the assumption that it is naturally disordered (44). A
high degree of flexibility in the CTT would provide distinct advantages to EGFR interaction with
downstream Src homology 2 (SH2) and phosphotyrosine-binding domains during signaling
functions (43).

In this work, we examine the biophysical properties of the CTT of EGFR and HER3. The
motivation of this study is to gather structural information on the CTT region to determine
whether the tails are highly dynamic, disordered regions. We expressed and purified EGFR and
HER3 CTT-only constructs and demonstrated that they are functional because they are
recognized and phosphorylated by EGFR family kinases and once phosphorylated can be bound
by the Grb2 SH2 domain. Using these CTT constructs, we performed multiple biophysical
analyses, including CD spectroscopy, size exclusion chromatography with multiangle light
scattering (SEC-MALS), dynamic light scattering (DLS), analytical ultracentrifugation (AUC),
and small angle X-ray scattering (SAXS). The results of these methods support the hypothesis
that the EGFR and HER3 CTTs are IDRs with extended, non-globular structure in solution.
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2.4 METHODS
Plasmids
DNA encoding residues 696–1022 of the human epidermal growth factor receptor was cloned
into pFAST BAC HT (Invitrogen) using the NcoI and HindIII restriction sites. This EGFR
wildtype kinase domain construct contains an N-terminal 6-His tag, a linker, and a TEV protease
cleavage site (MSYYHHHHHHDY DIPTTENLYFQGAM). For the EGFR CTT cloning, DNA
encoding residues 961–1186 of the human EGFR was cloned into a pET30b vector (Addgene)
using NdeI and XhoI restriction sites in-frame with a C-terminal His tag in the vector. Similarly,
DNA encoding residues 981–1342 of the human epidermal growth factor receptor 3 (HER3) was
cloned into a pET30b vector (Addgene) using NdeI and XhoI restriction sites in-frame with a Cterminal His tag in the vector. pGEX Grb2- SH2 (amino acids 58 –159) was purchased from
Addgene (plasmid 46440, deposited by Dr. Bruce Mayer). All plasmids were confirmed by DNA
sequencing.
Expression and purification of EGFR kinase domain:
The protein expression procedure was adapted from protocols described previously (4, 36).
Recombinant bacmid (Bac-to-Bac expression system, Gibco BRL) were transfected into
Spodoptera frugiperda Sf9 cells to produce recombinant baculovirus, which were used to infect
Sf9 cells grown at 27 °C and 120 rpm in IPL-41 medium (Invitrogen) supplemented with 10%
bovine calf serum supplemented (Hyclone), yeastolate extract (Invitrogen), penicillin,
streptomycin, and Pluronic F-68. Cultures at a density of 1 x 106 cells/ml were infected at 1 MOI
and cells were harvested 48 – 72hours post infection by centrifugation at 6000 rpm and
resuspended in Buffer A (25 mM Tris-HCl, pH 8, 300 mM NaCl, 10 mM imidazole, 5%
glycerol, 1 mM DTT) supplemented with phenylmethylsulfonyl fluoride, benzamidine, DNase,
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and protease inhibitor mixture tablets lacking EDTA (Roche). The cells were homogenized using
a probe sonicator and the lysate was centrifuged at 20000 rpm for 45 mins. 0.5 - 0.75 ml of NiNTA beads (Qiagen) were added to the supernatants and incubated on a rotator for 1 h at 4 °C.
The beads were poured into a 10-ml disposable column (Bio-Rad) and the flow-through
collected. The column was washed with 10 column volumes of Buffer A + 20 mM imidazole,
and the proteins were eluted with Buffer A + 50–125 mM imidazole. The eluted fractions were
further purified by gel filtration chromatography on a Superdex 200 GL 10/300 column (GE
Healthcare) using 20 mM Tris-HCl, pH 8, 150 mM NaCl, 1 mM DTT buffer. Pooled fractions
were concentrated and treated with TEV protease (at a mass ratio of 1mg of TEV protease to
40mg of EGFR kinase domain) overnight at 4C to remove the N-terminal His-tag. This was
bound to Ni-NTA beads and the flow-through was concentrated, snap frozen, and then stored 80
°C.
Expression and purification of EGFR CTT and HER3 CTT:
The E. coli strain BL21(DE3) was used for expression of the EGFR CTT construct. Transformed
cells were grown in Luria-Bertani medium containing 50 g/ml kanamycin at 37 °C until an
OD600 of between 0.5 and 0.8 was reached. Expression was induced through the addition of 0.5
mM isopropyl -D-1-thiogalactopyranoside (IPTG) for 3 h at 37 °C. Bacterial cells were
centrifuged at 6000 rpm, and the pellets were frozen. Cell lysis was performed at 4 °C with a
probe sonicator on frozen pellets using Buffer A (50 mM sodium phosphate, pH 8.0, 300 mM
NaCl, 20 mM imidazole, 1mM DTT) supplemented with 1 mM phenylmethylsulfonyl fluoride
(PMSF), 1mM -mercaptoethanol, Roche Applied Science protease inhibitor mixture tablets, 4
mM benzamidine HCl. The lysate was clarified by centrifugation at 48,000 x g for 30 min at 4
°C. Purification was performed using Nickel-chelating chromatography followed by gel filtration
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chromatography on a Superdex-75 column. The protein was concentrated to 5 mg/ml in 20 mM
phosphate, 150 mM sodium chloride, pH 8.0. Aliquots were snap frozen in liquid N2 and stored
at -80 °C. Protein concentration was determined using UV-visible spectroscopy with a molar
extinction coefficient of EGFR CTT at 280nm of  = 18,910 M-1cm-1. For specific subsequent
applications, the addition of tris(2-carboxyethyl) phosphine to EGFR CTT samples was critical.
A similar procedure was followed to express and purify the HER3 CTT but had trouble using
BL21 DE3 cells to express the construct. We used BL21 DE3 Rosetta cells to express milligram
amounts of the HER3 CTT. The use of the codon-optimized Rosetta cells was critical in
successful expression of the HER3 CTT. This was purified at a concentration of 2 mg/ml in
20mM Tris, 300mM sodium chloride, 5% (w/v) glycerol, pH 8.0. HER3 CTT concentration was
determined using a molar extinction coefficient at 280nm of = 25,245 M-1cm-1.
C-terminal Tail Function via Western Blotting Analysis:
EGFR CTT was phosphorylated via a reaction in 0.1 mM ATP, 0.1 mM sodium orthovanadate, 1
mM DTT and 1 mM MnCl2 catalyst. EGFR CTT concentrations of 0.25 M and 0.50 M tail
were incubated in the presence of 0.50 M EGFR kinase domain. Two negative controls were
also incubated under the same conditions with the following exceptions: 0.50 M CTT was
incubated without kinase domain present, and separately 0.50 M kinase domain was incubated
without CTT present. A positive control of ATP phosphorylation of 0.50 M EGFR ICH
construct, which contains both kinase domain and CTT regions together, was also incubated.
Two EGFR tail region-specific phosphotyrosines were analyzed by Western blotting. Following
the phosphorylation reaction, EGFR CTT samples were separated by SDS-PAGE on a 10%
polyacrylamide gel followed by electroblotting onto nitro-cellulose membrane. Two anti-EGFR
phosphotyrosine primary antibodies were used in separate Western blotting analyses: 1:1000
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anti-EGFR Tyr(P)-1068 and 1:5000 anti-EGFR Tyr(P)- 1173. Secondary antibody was 1:5000
anti-rabbit in both blots. The results of the Western blotting analyses are shown in figure 2.2.
The positive control was also analyzed on the same two Western blots as the EGFR CTT
samples. Bands from this positive control were observed on both Western blots but are not
shown herein. HER3 CTT was phosphorylated via the same buffer conditions as the EGFR CTT
above. HER3 CTT at 0.50 M was incubated in the presence of 0.50 M EGFR or 0.50 M
HER2 kinase domains. Negative controls were incubated under the same conditions where only
CTT or kinase domain was incubated in each case. Positive controls pairing HER3 ICH with
EGFR kinase domain or HER2 kinase domain were also incubated. Samples were separated by
SDS-PAGE and electroblotted onto nitrocellulose membrane. 1:1000 anti-HER3 Tyr(P)-1289
primary with 1:10,000 anti-rabbit secondary antibodies were used for the first blot. A 1:1000
general anti-phosphotyrosine anti- body, PY20, was used for the second blot with 1:10,000 antimouse secondary antibody. The two Western blots are shown in figure 2.2.
GST-Grb2-SH2 Expression and Purification:
BL21(DE3) cells were transformed, and a colony was picked and used to inoculate a 100 ml LB
ampicillin culture. The culture was induced to mid log phase with 1 mM IPTG for 2 hours at 37
°C. Pellets were collected and subsequently frozen at -80 °C. GST-Grb2-SH2 was purified using
glutathione-agarose beads (Sigma). Fractions were eluted with reduced glutathione, pooled,
dialyzed, and concentrated using an Amicon 10,000 molecular weight cutoff spin concentrator in
20mM Tris-HCl, pH 8 (4 °C), 150mM NaCl, 1mM DTT. Aliquots were flash frozen and stored
at -80 °C.
Interaction of Phosphorylated EGFR CTT and GST-Grb2- SH2 by Pulldown Assay:
EGFR CTT was phosphorylated by EGFR KD in vitro for 60 min at room temperature. 10 g of
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GST-Grb2-SH2 was prebound to a 10 l bed volume of glutathione-agarose beads. 2 g of either
phosphorylated CTT or non-phosphorylated CTT was added to the beads in a volume of 100 l
of buffer and incubated for 2 hours at 4 °C. Beads were then spun briefly and the flow-through
(FL) was collected. This was followed by two washes with buffer. Beads (bound) and aliquots of
the FL were then boiled in SDS-PAGE sample buffer. Western blotting was done on the
fractions using anti-His6-HRP antibody (Thermo Fisher, MA1-21314-HRP) as a probe.
Circular Dichroism Spectroscopy:
EGFR CTT protein was prepared at a concentration of 5 M in 10 mM sodium phosphate, pH
7.4, 5 mM NaCl. HER3 CTT was also prepared at the same conditions. A 0.1-cm path length
quartz cell was used for samples and buffer blanks. Cells were placed in a Jasco CD
spectrometer set at room temperature. The cell in the CD spectrometer was allowed to equilibrate
for 15 min with nitrogen flowing into the CD spectrometer before scans. The CD spectrometer
scanned from 260 to 190nm at 20 nm per min. Five individual scans were averaged, and the
buffer blank was subtracted before analysis. The CD spectra were analyzed on the DichroWeb
online analysis website (93, 94). The method chosen for this analysis used the CDSSTR
algorithm with reference database 7 as the reference protein set (95-98). Secondary structure
assignment was divided into six categories: regular -helix (R), distorted -helix (D), R,D,
turns, and unordered. CDSSTR structure assignment results are presented in figure 2.3C.
Size Exclusion Chromatography with Multiangle Light Scattering:
100 l of EGFR CTT or HER3 CTT (A280 ~ 1) was loaded onto a pre-equilibrated Superdex-75
10/300 GL (GE Healthcare) column. Elution buffer of 20 mM sodium phosphate, pH 8.0,
150mM NaCl, 0.5mM DTT was used for EGFR CTT, and 20mM Tris, 300mM sodium chloride,
5% (w/v) glycerol, pH 8.0 was used for HER3 CTT. The buffer flow rate was 0.5 ml/min for the
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EGFR CTT and carbonic anhydrase elutions. For the HER3 CTT and EGFR KD elutions, the
buffer flow rate was 0.3 ml/min. The column was coupled to a Wyatt Optilab rEX and Dawn
Helios II, which are refractive index and multiangle light scatter detectors, respectively.
Carbonic anhydrase was used as a globular reference for the EGFR CTT elution because of the
similar molecular weights of the proteins. Similarly, the EGFR KD was used as a reference for
the HER3 CTT elution. Astra (Wyatt) software was used to calculate the molar mass.
Dynamic Light Scattering:
EGFR and HER3 CTT samples at a concentration of 0.5 mg/ml in 20 mM Tris, 150 mM NaCl, 1
mM DTT, pH 8.0, were centrifuged for 5mins. 12 l of sample was aliquoted into a clean
microcuvette, which was placed into a Wyatt Dynapro MSX. The cuvette was equilibrated for 5
min at 25 °C before data acquisition. BSA was used as a standard at 1.0 mg/ml in the same
buffer. Dynamics software was used to determine the radius of the protein.
Analytical Ultracentrifugation:
Samples were dialyzed against Buffer A (20 mM sodium phosphate, pH 8.0, 150 mM NaCl, 1
mM DTT) for EGFR CTT or Buffer B (20mM Tris, 300mM sodium chloride, 5% (w/v) glycerol,
1 mM DTT, pH 8.0) for HER3 CTT at 4 °C overnight. The samples and buffer were recovered
and briefly centrifuged before loading into centrifuge cells. The cells were balanced and then
placed in an eight-position rotor, which was put into a Beckman XLA ultracentrifuge. The speed
was 42,000 rpm, and the temperature was 25 °C. The SEDFIT program was used to analyze the
data, and the resulting c(s) analysis is shown in figures 2.4E and F (99).
Small Angle X-ray Scattering Analysis:
SAXS experiments were performed on the SIBYLS beamline 12.3.1.2 at the Advanced Light
Source, a national user facility operated by the Lawrence Berkeley National Laboratory
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(Berkeley, CA) and supported by the Director, Office of Science, Office of Basic Energy
Sciences of the United States Department of Energy under Contract DE-AC02-05CH11231
(100). To optimize the data quality and minimize radiation damage, exposure series of 0.5, 1, 2,
and 5 sec were performed. The concentration of EGFR CTT (20 mM phosphate, pH 8.0, 150
mM NaCl) used for these experiments ranged from 0.9 to 3.7 mg/ml. BSA in 20 mM phosphate,
pH 8.0, 150 mM NaCl was used as a standard in the range of 1.0 –3.0 mg/ml. The concentration
of HER3 CTT (20mM Tris-HCl, pH 8.0, 300mM NaCl, 5% glycerol, 1 mM DTT) ranged from
0.9 to 1.5 mg/ml. A minimum of three different concentrations for each protein were used for
data collection, and five different concentrations were used for EGFR CTT. The data sets were
processed using standard procedures for ATSAS programs (101). At low angles, the scattered
intensities of EGFR CTT and HER3 CTT were very well approximated by the Guinier law,
whereas HER3 CTT showed signs of radiation damage at 5 sec exposures. Before further
analysis, the scattering curves, free of radiation damage, from a given type of sample with the
same protein concentration but different exposure times were merged with either PRIMUS (101)
or SCÅTTER (SIBYLS Beamline at Lawrence Berkeley National Laboratory) and then averaged
among the same type of sample after normalization using their individual protein concentration.
The average scattering curves are presented in figures 2.5A and 2.6A. The Rg from data sets free
of radiation damage was calculated using AutoRg and is presented in Table 2.2. We evaluated
the molecular weight of the sample by comparing the forward scattering I(0) with that from a
reference solution of BSA. The Rg and Dmax values for EGFR kinase domain (Protein Data Bank
code 1XKK) were calculated using the program CRYSOL (102). The pair distribution functions
for EGFR CTT and BSA were generated using Datgnom (101).
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2.5 RESULTS
Disorder Predictions on EGFR, HER2, and HER3
We used computation algorithms to provide an initial survey of disordered regions in the
EGFR/ErbB family of RTKs. Predictor of natural disordered regions (PONDR) is a collection of
algorithms that use an amino acid sequence to predict native disorder (103,104). The VL-XT
algorithm assigns a disorder propensity score for disorder on a residue by residue basis (101105). The VL-XT prediction for EGFR, HER2, and HER3 can be seen in figure 2.1. PONDR
scores greater than 0.5 indicate predicted disorder, and scores less than 0.5 indicate predicted
order. Kinase domains of the three EGFR/ErbB family members show mostly predicted order,
whereas the CTT in each shows large regions of predicted disorder. The amino acid composition
of the CTT and kinase domains of both EGFR and HER3 is shown in Table 2.1. When
comparing the CTTs with the kinase domains in both proteins, we observe that the CTTs are
more enriched in polar, uncharged residues and prolines but relatively depleted in hydrophobic
residues. For EGFR, polar, uncharged residues make up 30.1% of the CTT versus 14.9% of the
kinase domain. Prolines make up 10.6% of the EGFR CTT versus 5.4% in the kinase domain,
and hydrophobic residues (excluding tyrosine, which can become phosphorylated) are 27.4% of
the EGFR CTT versus 38.9% of the kinase domain (Table 2.1). Similar values are seen with
HER3 CTT (Table 2.1) despite its primary sequence divergence from EGFR CTT (22%
sequence identity between EGFR and HER3 CTT; calculated with Clustal Omega) (106). The
lowered hydrophobicity provides a simple explanation as to why the tails would not form a
hydrophobic core and therefore be disordered in an aqueous environment. These predictions are
a useful tool for gaining a general view of disordered regions in a protein sequence, but direct
empirical evidence would better support the hypothesis of the CTTs as being IDRs.
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Figure 2.1. Disorder prediction by PONDR VL-XT algorithm. Shown are the disorder
predictions for EGFR, HER2, and HER3 ICD construct sequences. In all three graphs, results for
the kinase domain residues are colored blue, and the tail domain residues are colored in red. A
score above 0.5 indicates predicted disorder while a score below 0.5 indicates predicted order.
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Table 2.1. EGFR and HER3 amino acid composition analysis by region

Expression of EGFR and HER3 C-terminal Tails
To further characterize the conformational and physical state of the EGFR and HER3 CTTs, we
expressed and purified EGFR and HER3 CTT-only constructs in a bacterial Escherichia coli
system. EGFR residues 961–1186 with a C-terminal His tag were purified using nickelnitrilotriacetic acid column chromatography and gel filtration. Estimated purity by SDS-PAGE
was 95% (figure 2.2.A) with a concentration of 5 mg/ml. The HER3 CTT, HER3 residues 981–
1342, was also expressed in E. coli and purified to a concentration of 2 mg/ml with 95% purity in
the same manner (figure 2.2.B).
Confirmation of EGFR C-terminal Tail Function
Phosphorylation of the CTT region and subsequent binding of SH2 domain-containing proteins
are essential steps in EGFR signaling. We first validated the ability of our CTT constructs to be
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both recognized and phosphorylated at specific tyrosine sites by separate EGFR family kinase
domains in solution just as they would be if they were part of their respective ICH constructs. To
test whether the E. coli-expressed EGFR CTT construct is functional, we incubated it with
recombinant EGFR kinase domain and measured tail phosphorylation using reaction with ATP
and blotting with phosphospecific antibodies. We show, through Western blotting identification
of specific phosphorylated tyrosine residues (EGFR Tyr-1068 and Tyr-1173) in the EGFR CTT
(figure 2.2.C), that the EGFR CTT is recognized and phosphorylated by the EGFR kinase
domain even when these two domains are expressed as separated constructs. Further- more, we
used anti-HER3 Tyr(P)-1289 and general PY20 anti- bodies to verify that the HER3 CTT was
phosphorylated by both the EGFR kinase domain and HER2 kinase domain via Western blotting
(figure 2.2.D). Next, we tested whether EGFR CTT can be bound by an SH2 domain-containing
protein. We recombinantly expressed GST-tagged Grb2 SH2 domain and performed a GST
pulldown assay (figure 2.2.E). Incubating EGFR CTT with EGFR kinase domain produced a
phosphorylated CTT that appeared as multiple bands of higher molecular weight, and this
phosphorylated EGFR CTT did not bind on its own to glutathione-agarose (figure 2.2E, flowthrough in lane 1 and bound in lane 2). Similarly, incubating unphosphorylated EGFR CTT with
the GST-Grb2 SH2 domain construct did not result in binding, and EGFR CTT eluted in the
flow-through (lane 3). However, once phosphorylated, EGFR CTT was bound by GST-Grb2SH2 and was pulled down by glutathione-agarose (figure 2.2.E, lane 6). These experiments
provide evidence for the functionality of the EGFR and HER3 CTT constructs.
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Figure 2.2. Purification and Phosphorylation of C-Terminal Tail (CTT) constructs. A,
Coomassie stained SDS-PAGE gel of EGFR CTT purification. Lanes 1 and 4 are molecular
weight markers, labeled respectively. Lane 2 is transformed cell lysate pre-induction with IPTG.
Lane 3 is lysate post-induction. Lane 5 is purified EGFR CTT following Ni2+ chelating
chromatography and gel filtration. EGFR CTT purity determined to be >95%. B, Coomassie
stained SDS-PAGE gel of HER3 CTT purification. This gel uses similar lane arrangement as in
figure 2.2.A for HER3 CTT expression. C, EGFR CTT is recognized and phosphorylated by the
EGFR kinase domain. Phospho-specific antibodies to EGFR pY1068 and EGFR pY1173 were
used to detect CTT phosphorylation. D, Western blot analysis of HER3 CTT phosphorylation.
The HER3 ICH serves as a positive control showing C-terminal tail phosphorylation via
interaction with EGFR KD or HER2 KD. HER3 CTT is recognized and phosphorylated by the
EGFR and HER2 kinase domains, just as it would be as if it was part of its ICH construct.
Phospho-specific antibodies to HER3 pY1289 and general anti-phosphotyrosine pY20 were used
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to detect HER3 CTT phosphorylation. E, Phosphorylated EGFR CTT binds to the Grb2-SH2
domain. GSH-agarose beads were pre-loaded with GST tagged Grb2-SH2 domain protein.
Phosphorylated or unphosphorylated EGFR CTT was then incubated with the beads for 2 hours
at 4 °C, flow-through (FL) collected, washed, then the beads were boiled in sample buffer
(Bound). SDS-PAGE of fractions then transferred to Nitrocellulose. Anti His6-HRP Ab was used
to detect EGFR CTT in the FL and bound fractions.

Analysis of EGFR CTT by CD Spectroscopy
Far-UV CD spectroscopy provides information about the secondary structure characteristics of
protein molecules in solution based on the absorption of circularly polarized light by amide
bonds in the polypeptide backbone. Because secondary structure types absorb circularly
polarized light differently and each amide bond contributes to the UV absorption, the resulting
spectrum will reflect a global average of the secondary structure content in a protein. Due to a
lack of -helix and -sheet content, mostly or fully disordered and unfolded proteins will have CD
spectra that are distinct from highly ordered proteins. The CD spectra between 190 and 260 nm
wavelengths for EGFR CTT and HER3 CTT are shown in figure 2.3, A and B, respectively.
Distinctive features expected for a mostly -strand protein would include a positive ellipticity
maximum at 195nm with a negative ellipticity minimum near 215 nm. For a mostly -helical
protein, one would expect two minima, one at 208 nm and the other at 224 nm wavelength, along
with a pronounced maximum near 192nm (55, 93). However, the CD spectrum observed for
EGFR CTT shows a minimum between 195 and 200 nm, which is a characteristic of disordered
proteins (figure 2.3.A). However, the slightly negative ellipticity at 222nm indicates the
possibility of residual secondary structure. Analysis via the CDSSTR algorithm, an algorithm
32

used to assign secondary structure composition to CD spectra, shows 77% unordered character in
the EGFR CTT spectrum (figure 2.3.C). These results suggest that much of the EGFR CTT
construct has an unfolded conformation in solution. The CD spectrum for HER3 CTT shows
similar features as the EGFR CTT with a minimum between 195 and 200 nm and slightly
negative ellipticity at 222 nm (figure 2.3.B). The HER3 CTT has mostly unordered content
(60%) but slightly higher β-sheet content than EGFR CTT: regular -strand (R) 15% and
distorted -strand (D) 7% for HER3 CTT as compared with R 6% and D 3% for EGFR CTT
(figure

2.3.C).

Figure 2.3. Circular dichroism spectroscopy. A, The CD spectrum for the EGFR CTT
construct does not show prominent spectral features of α-helices and β-sheets. B, Similarly, the
HER3 CTT CD spectrum shows high unordered content, with slightly higher calculated β-sheet
content than in the EGFR CTT spectrum. C, Secondary structure assignment was assigned the
following symbols: regular α-helix (αR), distorted α-helix (αD), regular β-strand (βR), distorted
β-strand (βD), turns (T), and unordered (U).
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Size Exclusion Chromatography with Multiangle Light Scattering
Another property of intrinsically disordered regions is a higher than expected apparent molecular
mass during gel filtration separations (59). SEC can be used to separate proteins based on their
hydrodynamic size, which is increased in IDRs depending on the degree of conformational
extension. Proteins with higher hydrodynamic size elute earlier than smaller proteins, and
accurate, absolute measurement of molecular weight can be obtained by coupling SEC to a
MALS detector (60). Figure 2.4.A shows the SEC elution chromatograms for both the EGFR
CTT and carbonic anhydrase with the coupled MALS detection inserted above. Our analysis
shows that EGFR CTT and carbonic anhydrase share similar molecular masses at 26 and 29kDa,
respectively, and both are monomeric under these conditions. EGFR CTT elutes from the SEC
column before 13 ml of buffer volume. Despite having a lower molecular weight, the EGFR
CTT elutes earlier than carbonic anhydrase, which elutes just after 15 ml of buffer. The expected
Stokes radius of carbonic anhydrase is 2.4 nm (107). This earlier elution indicates that the EGFR
CTT conformational ensemble is more extended than that of carbonic anhydrase, which has a
globular structure. Figure 2.4.B shows the SEC-MALS chromatogram profiles for HER3 CTT
and EGFR kinase domain. The molecular masses, determined by MALS, of the HER CTT and
EGFR kinase domain were 42 and 38 kDa, respectively. HER3 CTT eluted at about 14 ml of
buffer, which is earlier than the EGFR kinase domain, which eluted between 16 and 17 ml of
buffer. As with EGFR CTT, no multimeric peaks were observed in the HER3 CTT
chromatogram.
Dynamic Light Scattering
The DLS technique is used to analyze hydrodynamic properties of proteins in solution. Using the
hydrodynamic radius, or Stokes radius, derived from measurements of translational diffusion
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coefficients, we are able to differentiate between a protein ensemble with mostly compact,
globular conformations and one with more extended conformations as would be seen for IDRs
(61). DLS is complementary to the static light scattering used in SEC-MALS in that DLS
provides information on molecular size, whereas MALS provides a molecular weight and
verification of a monomeric state. A histogram showing a distribution of measured
hydrodynamic radii within the EGFR CTT and bovine serum albumin (BSA) populations is
shown in figure 2.4.C. The EGFR CTT, which has a molecular mass of 26kDa, was determined
to have a hydrodynamic radius of 5.3 nm. For a comparison, we also analyzed BSA, a globular
protein with a molecular mass of 66 kDa, and the hydrodynamic radius of BSA was measured to
be 4.8 nm. This demonstrates that EGFR CTT has a larger hydrodynamic radius than a globular
protein more than 2.5 times its size. Similarly, HER3 CTT has a very large hydrodynamic radius
(figure 2.4.D). The hydrodynamic radius (RH) of HER3 CTT is 6.4 nm, although it has higher
polydispersity than EGFR CTT.
Analytical Ultracentrifugation
We used sedimentation velocity AUC to determine the sedimentation coefficient, s, of EGFR
CTT, which provides information about the molecular weight of the tail, Mf, as it relates to its
RH (figure 2.4.E). We also determined that our sample is homogenous due to the absence of
secondary peaks in figure 2.4C as secondary populations or impurities would have different
sedimentation velocities. From these AUC measurements, we obtained the frictional coefficient
of the tail, f, which can be used to relate its molecular shape to that of a globular protein. The
frictional ratio, f/fmin, provides an indication of the shape of a macromolecule based on the ratio
of its measured frictional coefficient to a theoretical minimum frictional coefficient for a particle
with minimum Stokes radius at a given molar mass (62). For a globular protein, the expected
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f/fminwouldfallbetween1.15and1.3 (108-110). We determined the f/fmin value for EGFR CTT to
be much greater, at 1.77, which is consistent with this being an IDR. Similarly, HER3 CTT has
an f/fmin value of 1.52, which is also greater than the expected frictional ratio for globular
proteins (figure 2.4F).
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Figure 2.4 Hydrodynamic Properties of EGFR CTT. A, Elution chromatograms and molecule
weight determination of EGFR CTT by SEC-MALS. EGFR CTT data is shown in red, carbonic
anhydrase data is shown in blue. Despite similar molecular weights, EGFR CTT elutes sooner,
indicating a larger hydrodynamic size. B, SEC-MALS analysis of HER3 CTT. HER3 CTT data
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is shown in red, EGFR kinase domain data is shown in blue. Again, the two molecules share
similar molecular weights, but HER3 CTT elutes sooner than the EGFR KD. C, Hydrodynamic
radius determination of the EGFR CTT and BSA by dynamic light scattering. The measured
DLS hydrodynamic radius distribution for EGFR CTT is shown as yellow bars. The measured
hydrodynamic radius of EGFR CTT is 5.3 nm. The histogram for BSA (monomeric fraction
obtained by gel-filtration) is shown as red bars. The RH of monomeric BSA is 4.8 nm. D,
Hydrodynamic radius determination of the HER3 CTT. The measured DLS hydrodynamic radius
for HER3 CTT is 6.4 nm. E, Frictional coefficient, frictional ratio, and molecular weight
determined by analytical ultracentrifugation. Sedimentation coefficient is used to measure an
apparent molecular weight of Mf = 23.5 kDa. The frictional ratio for the EGFR CTT is 1.77,
indicating a large Stokes radius relative to globular proteins. F, Frictional coefficient, frictional
ratio, and molecular weight determined by analytical ultracentrifugation. The measured apparent
molecular weight of HER3CTT is 31.6 kDa. The frictional ratio is 1.52.
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Small Angle X-ray Scattering
Small angle X-ray scattering methods have been particularly useful in analyzing conformation
ensemble properties of IDRs (63). In small angle X-ray scattering analyses, we measured the
isotropic scattering intensity, I(s), as a function of the momentum transfer, s, of monochromatic
X-ray light diffracted by protein macromolecules in solution. In protein structure studies, SAXS
has been used to characterize structure and dynamics of monodisperse molecular species with a
dominating structural configuration. IDRs show larger average sizes compared with globular
proteins that contain tightly packed cores. By comparing the measured Rg and Dmax from SAXS
with other known structured globular proteins, together with Kratky plots (I(s)s2 as a function of
s), which characterizes the flexibility state of the proteins, one is able to identify the flexibility of
the IDRs (111). Figure 2.5.A shows the scattering profiles for EGFR CTT and BSA. In figure
2.5.B, Guinier plot regions of EGFR CTT in three different concentrations are shown. Rg values
calculated by AutoRg (101) are 46.6  2.2 (EGFR CTT) and 33.6  0.6 Å (BSA), and the
molecular masses for each of them are 25.6  0.7 and 69.0  2.0 kDa, respectively (Table 2.2.).
The Kratky plot (figure 2.5.C) of BSA shows a parabolic shape with a well-defined peak. In
contrast, EGFR CTT shows a hyperbolic shape on the Kratky plot, indicating an intrinsically
disordered region (figure 2.5.C). Figure 2.5D shows the pair distribution function (P(r)) of
EGFR CTT generated by Datgnom (100). The Dmax of EGFR CTT is 156  6 Å, which is much
larger than that of BSA (Table 2.2.). Thus, the Rg and Dmax measurements, Kratky plot, and
P(r) distribution of EGFR CTT indicate that the conformational ensemble adopted by EGFR
CTT is extended and flexible. When we analyzed the HER3 CTT with SAXS, we also included
samples containing urea to determine whether a chemical denaturant would have an effect on the
conformational ensemble. It is also important to note that, unlike in EGFR CTT buffer, 5%
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glycerol was also included in the HER3 CTT buffer. The glycerol was necessary to maintain
protein solubility and stability of the HER3 CTT, but it may also act to stabilize conformations
with diminished extendedness. We do not directly compare derived Rg values between EGFR
CTT and HER3 CTT because of this difference in buffer conditions. The scattering profiles for
HER3 CTT without urea and with 4 M urea are shown in figure 2.6A, and Guinier plot regions
are shown in figure 2.6B. From these data, we calculated an Rg of 45.4  0.4 Å in the absence of
urea, and that increases slightly to 50.5  1.2 Å upon the addition of 4M urea (Table 2.2.). The
derived Kratky profiles for these two conditions are shown in figure 2.6.C. Without urea present,
the HER3 CTT produces a slightly parabolic Kratky profile, with a defined local maximum
observed, at lower momentum transfer values. Moving toward greater momentum transfer values
then gives a more hyperbolic increase in I(s)s2. For HER3 CTT with 4 M urea, the Kratky profile
has a hyperbolic shape indicative of disorder, similar to the profile observed for the EGFR CTT
(figure 2.5.C). The difference in Kratky plots between HER3 CTT with or without urea, together
with increased Rg, indicates that HER3 CTT possesses characteristics of IDRs but not of random
coil structures when in solution.
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Figure 2.5. Small angle X-ray scattering analysis of EGFR CTT. A, Scattering profiles of
EGFR CTT (red) and BSA (blue). B, Guinier plots of EGFR CTT in different concentrations,
0.9, 1.8, and 3.7 mg/ml. C, The data is represented in a Kratky Plot with arbitrary units. In folded
proteins like BSA (blue), Kratky plot shows parabolic features. While in the EGFR CTT Kratky
plot (red), a hyperbolic shape indicates intrinsically disordered protein character. D, Pair
distribution functions for the EGFR CTT (red) and BSA (blue) scattering profiles, generated
using Datgnom (55).
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Figure 2.6 Small angle X-ray scattering analysis of HER3 CTT in solution ± urea. A,
Scattering profiles of HER3 CTT in solution without urea (blue) and with 4M urea (red). B,
Guinier plots of HER3 CTT with or without the presence of 4 M urea. C, The data is represented
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in a Kratky Plot with arbitrary units. The Kratky Plot for HER3 CTT with 4M urea additive
shows a more hyperbolic profile, indicating greater disorder with the addition of chemical
denaturant.
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Table 2.2. Structural parameters observed by SAXS.
a

Values were calculated based on protein amino acid sequences.

b

Measured MW was calculated from the X-ray scattering profile.

c

Buffer for EGFR CTT was 20mM Phosphate pH 8.0, 150mM NaCl

d

Buffer for Her3 CTT was 20mM Tris-HCl pH 8.0, 300mM NaCl, 5% glycerol, +/- 4M Urea as indicated

above.
e

Values of EGFR kinase domain were calculated from a theoretical scattering profile generated by the

Crysol program using the crystal structure of EGFR kinase domain (PDB accession number 1XKK).
f

Characteristics of intrinsically disordered proteins are shown in the Kratky plots for these constructs.
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2.6 DISCUSSION
We have shown that the CTT domains in EGFR family proteins are intrinsically disordered
regions that have an extended, highly dynamic conformational state. CD spectroscopy shows that
they have high unordered character as expected for IDRs. SEC and DLS demonstrate that
hydrodynamic size of the CTT is larger than protein standards of comparable molecular weight,
which is another property of IDRs. AUC and the Kratky plot from SAXS demonstrate that the
CTTs are IDRs, and Rg and Dmax measurements from SAXS demonstrate that the CTTs have an
extended conformation. The Rg and Dmax measurements of the EGFR kinase domain were
estimated from crystal structure (Protein Data Bank code 1XKK), and we observed that the
EGFR CTT had Rg and Dmax values that were 2.4 times larger than those of the EGFR kinase
domain. A striking finding on the EGFR and HER3 CTTs is that despite their low primary
sequence homology (22% sequence identity) the structural features of the CTTs are strongly
conserved. This implies that the intrinsic disorder of these tails is important for their function,
and the multiple conformers that a disordered region can adopt could reduce the thermodynamic
barriers for protein binding and thereby increase both the on- and off-rates for binding of SH2
domain-containing proteins. Furthermore, the extended conformation of the CTT could increase
the capture radius for recruitment of these signaling proteins (112, 113). Both mechanisms would
facilitate signal propagation by these receptor tyrosine kinases. The intrinsically disordered
properties of these CTTs also explain why these regions are mostly absent from crystallographic
studies on EGFR (47, 82). In conclusion, these methods demonstrate that the EGFR and HER3
CTTs are IDRs with extended, non-globular structure in solution, and this finding may have
important implications for the recruitment of downstream signaling proteins and signal
propagation from these RTKs.
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Chapter 3: Efficient sortase-mediated N-terminal labeling of TEV
protease cleaved recombinant proteins
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This chapter was adapted from:
Sarpong K, Bose R. (2017) Efficient Sortase-mediated N-terminal Labeling of TEV
Protease Cleaved Recombinant Proteins. Anal. Biochem. 15, 55 – 58.
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3.2 ABSTRACT
A major challenge in attaching fluorophores or other handles to proteins is the availability of a
site-specific labeling strategy that provides stoichiometric modification without compromising
protein integrity. We developed a simple approach that combines TEV protease cleavage, sortase
modification

and

affinity

purification

to

N-terminally

label

proteins.

To

achieve

stoichiometrically-labeled protein, we included a short affinity tag in the fluorophore-containing
peptide for post-labeling purification of the modified protein. This strategy can be easily applied
to any recombinant protein with a TEV site and we demonstrate this on Epidermal Growth
Factor Receptor (EGFR) and Membrane Scaffold Protein (MSP) constructs.
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3.3 INTRODUCTION
Site-specific protein labeling is the method of choice for most biochemical and
biophysical applications, as this offers a high level of precision for the attachment of a
fluorophore or other chemical moiety (69, 70). Due to the relatively low abundance of cysteines
in proteins (71), chemical labeling of proteins using maleimide chemistry is a common strategy
for most applications.

However, many proteins contain multiple cysteine residues and

mutagenesis of these cysteines is time-consuming and may compromise protein function. An
alternate approach is to label primary amines with N-hydroxysuccinimide ester-based
fluorophores. However, the relatively high abundance of lysines and pKa requirements renders
the utility of amino groups for protein modification a less commonly used strategy. These
challenges are compounded by long reaction times to ensure complete modification of the
protein. With fluorophores having a MW of <1kDa, separation of labeled products from the
unlabeled protein can also present challenges. Sub-stoichiometric labeling often results in a
diminished signal-to-noise ratio and impacts the utility of fluorophore-labeled proteins for
biophysical studies.
Enzymatic approaches for site-specific incorporation of fluorophores are an alternative to
these chemical labeling strategies. Sortases are membrane-associated transpeptidases that anchor
Gram-positive bacterial surface proteins to their cell walls. Since the discovery of sortases,
Staphylococcus aureus sortase A (SrtA) has been the prototype for understanding the mechanism
of action of these enzymes (73). Proteins anchored to the bacterial cell wall by SrtA possess a Cterminal sorting signal that contains a hydrophobic domain sandwiched between the conserved
LPXTG recognition motif and a positively charged tail (73). SrtA catalyzes the hydrolysis of the
peptide bond between the threonine and glycine residues to generate an acyl-enzyme
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intermediate that is subsequently attacked by an oligoglycine peptide in a nucleophilic attack
(74). This results in the formation of a new peptide bond between the incoming nucleophilic
glycine-containing peptide and the protein. Seminal work (by Schneewind and coworkers) that
laid the ground for its utility in biochemical and biotechnological studies showed a recombinant
peptide containing the LPXTG motif alone is sufficient for recognition and catalysis (75). These
studies also indicated that a peptide containing 1-3 N-terminal glycines could replace the
peptidoglycan involved in the sortase-mediated reaction (75). Current biochemical evidence has
suggested that only one additional residue (preferably a glycine) is required at the C-terminus of
the LPXTG recognition sequence for efficient sortase binding and catalysis (76).
Most recombinant proteins used for biochemical and biotechnological applications
contain affinity tags that ensure their easy and efficient purification (114, 115). Sandwiched
between the affinity tags and the proteins are protease recognition sites that offer the cleavage of
the affinity tags following purification. Commonly used recognition sites include TEV, Factor
Xa, and Thrombin protease cleavage sites. An important requirement for the sortase reaction is
the generation of the N-terminal glycine residue which can be done by removing the initial
methionine of an expressed protein using methionylaminopeptidase or engineering a thrombin or
TEV protease recognition site that exposes an N-terminal glycine following cleavage (116).
Recent years have seen the development and utility of sortase to modify proteins at their
carboxyl and amino termini in addition to internal loops (76, 77). Unlike traditional chemical
strategies that are easy to use, protein modification employing short genetically encoded tags
such as the LPXTG-tag, ACP-tag and LAP-tag offer a high degree of precision. However, back
reaction from the final product (containing the LPXTG motif and therefore an efficient substrate
for the sortase enzyme) and the reversible nature of the sortase reaction can lead to sub52

stoichiometric protein modification and decreased labeling efficiencies. To address this
challenge, the equilibrium of the reaction is driven towards product formation by increasing the
fold excess of the fluorophore-containing peptide (76, 77). Recent methodologies to address this
issue of irreversibility have included the use of a sortase-tagged expressed protein ligation
(STEPL) system that circumvents the removal of unconjugated species (117), dialysis to remove
reaction by-products (118) and the introduction of tryptophan-derived zippers around the SrtA
recognition motif that induces the formation of a stable β-hairpin (119). Other research groups
have solved this problem by utilizing a depsipeptide, which replaces the amide bond between the
threonine and glycine residues with an ester linkage (120). These challenges make protein
modification using sortase cumbersome and potentially expensive when the fluorophorecontaining peptide is needed in many fold excess. The presence of reaction by-products as a
result of back reaction and the reversible nature of the reaction affect the purity and degree of
labeling of the final product, and subsequently present challenges in the utilization of
fluorophore-labeled proteins.
We have developed a simple approach that combines TEV protease cleavage, sortase
modification

and

affinity

purification

to

N-terminally

label

proteins.

To

achieve

stoichiometrically-labeled product, a short affinity tag is included in the fluorophore-containing
peptide so that post-labeling affinity purification of only the labeled protein can be performed.

53

3.4 METHODS
Plasmids
Staphylococcus aureus sortase A plasmid was generously provided by the Ploegh lab (MIT).
This sortase A pentamutant (SrtA 5M) is Ca2+ -dependent and had previously undergone directed
evolution to be catalytically more efficient (121). SrtA 5M contains five mutations and has a
140-fold increase in transpeptidase activity over wildtype SrtA. We engineered SrtA 5M to have
a TEV cleavage site before the C-terminal histidine tag, to facilitate our downstream purification
strategy. Sequences of all the plasmids were confirmed by DNA sequencing.
Expression, purification and TEV protease cleavage of EGFR kinase domain constructs:
We expressed and purified the EGFR kinase domain using a protein expression protocol
described previously (4, 36). Recombinant bacmid (Bac-to-Bac expression system, Gibco BRL)
was transfected into Spodoptera frugiperda Sf9 cells to produce recombinant baculovirus, which
were used to infect Sf9 cells grown at 27 °C and 120 rpm in IPL-41 medium (Invitrogen)
supplemented with 10% bovine calf serum supplemented (Hyclone), yeastolate extract
(Invitrogen), penicillin, streptomycin, and Pluronic F-68. Cultures at a density of 1 x 106 cells/ml
were infected at 1 MOI and cells were harvested 48 – 72hours post infection by centrifugation at
6000 rpm and resuspended in Buffer A (25 mM Tris-HCl, pH 8, 300 mM NaCl, 10 mM
imidazole, 5% glycerol, 1 mM DTT) supplemented with phenylmethylsulfonyl fluoride,
benzamidine, DNase, and protease inhibitor mixture tablets lacking EDTA (Roche). The cells
were homogenized using a probe sonicator and the lysate was centrifuged at 20000 rpm for 45
mins. 0.5 - 0.75 ml of Ni-NTA beads (Qiagen) were added to the supernatants and incubated on a
rotator for 1 h at 4 °C. The beads were poured into a 10-ml disposable column (Bio-Rad) and the
flow-through collected. The column was washed with 10 column volumes of Buffer A + 20 mM
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imidazole, and the proteins were eluted with Buffer A + 50–125 mM imidazole. The eluted
fractions were further purified by gel filtration chromatography on a Superdex 200 GL 10/300
column (GE Healthcare) using 20 mM Tris-HCl, pH 8, 150 mM NaCl, 1 mM DTT buffer.
Pooled fractions were concentrated and treated with TEV protease (at a mass ratio of 1mg of
TEV protease to 40mg of EGFR kinase domain) overnight at 4C to remove the N-terminal Histag and generate an EGFR kinase domain with an N-terminal glycine, Gly-EGFR. This was
bound to Ni-NTA beads and the flow-through was concentrated, snap frozen, and then stored 80
°C. We also expressed and purified two other EGFR kinase domain constructs, whose TEV
cleavage resulted in two and four N-terminal glycines, Gly2-EGFR and Gly4-EGFR respectively.
Expression, purification and TEV protease cleavage of Sortase A protein constructs
The protocol we used for expressing and purifying SrtA 5M (with and without the TEV cleavage
site) had been previously described (76). Briefly, BL21 (DE3) competent E. coli cells were
transformed with pET30b S. aureus sortase A 5M or pET30b S. aureus sortase A 5M (containing
an insertion for TEV protease cleavage) onto LB-kanamycin plates. An individual colony was
picked and inoculated into 100 mL LB-ampicillin and placed in a shaker at 220 rpm at 37 °C
overnight. 10 mL of the overnight culture was diluted into 1 L LB media with the corresponding
kanamycin. This was grown at 37°C until OD600 of 0.4–0.6 (~3 h) was achieved. Expression was
induced through the addition of 0.5 mM isopropyl -D-1-thiogalactopyranoside (IPTG) for 16 h at
25 °C. The bacterial cells were centrifuged at 6,000 x g for 15 min at 4 °C. The pellet was
resuspended in 50 ml Nickel-binding buffer (50 mM Tris-HCl, pH 7.5 and 150 Mm NaCl),
transferred to a 50 ml centrifuge tube, centrifuged again and the pellet frozen at −80 °C. Cell
lysis was performed at 4 °C with a probe sonicator on frozen pellets using 25 ml ice cold lysis
buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM MgCl2, 10 mM imidazole, 10% (vol/vol)
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glycerol, 1 mg ml−1 DNase and 1 mg ml−1 lysozyme). The lysate was clarified by
centrifugation at 20,000 x g for 30 min at 4 °C. A Poly-prep column was packed with 1–1.5 mL
(bed volume) nickel-nitrilotriacetic acid (Ni-NTA) agarose resin and washed with 10 column
volumes of wash buffer (by gravity flow) and the bacterial supernatant loaded onto the column
(by gravity flow). The column was then washed with 50 column volumes of wash buffer to
remove nonspecifically bound proteins and proteins eluted with 3 column volumes ice-cold
elution buffer (50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 500 mM imidazole and 10% (vol/vol)
glycerol). The protein was buffer exchanged and concentrated to 15 mg/ml in Nickel-binding
buffer (no imidazole) + 10% imidazole. A fraction was aliquoted into tubes, snap frozen in liquid
N2 and stored at -80 °C. The SrtA 5M construct containing a TEV cleavage site was treated with
TEV protease (at a mass ratio of 1mg of TEV protease to 40mg of SrtA) overnight at 4C to
remove the N-terminal His-tag. This was bound to Ni-NTA beads and the flow-through was
concentrated, snap frozen, and then stored 80 °C. Protein concentration was determined using
UV-visible spectroscopy with a molar extinction coefficient of SrtA 5M (with a TEV cleavage
site) at 280nm of = 15,930.
Enzymatic activity of SrtA 5M constructs
The sortase activity of the wildtype SrtA 5M and SrtA 5M containing a TEV cleavage site was
determined using an already published protocol (122). We used a self-fluorescent quenching
peptide, o-aminobenzoyl-LPETG-2,4-dinitrophenyl as a substrate in the cleavage reaction
containing 1.5 M SrtA enzyme dissolved in assay buffer (20 mM HEPES, pH 7.5, 10mM
CaCl2). The o-aminobenzoyl-LPETG-2,4-dinitrophenyl substrate was dissolved in dimethyl
sulfoxide and added to the reaction to a final concentration of 6.25 M, for a total reaction
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volume of 37.5 l. The samples were incubated at 37 C for 1 hr and analyzed in a
spectrophotometer using 340 nm for excitation and recording the emission maximum at 420 nm.
Design and fluorophore-labeling of peptides
The LPETGG sortase substrate was made using solid-phase synthesis on a Wang resin.
Following removal of the Fmoc on the -aminocaproic acid residue, 3 molar equivalents of 5(6)TAMRA succinimidyl ester was added and the column wrapped in aluminum foil. This was
shaken overnight at room temperature. The resin was cleaved in a solution consisting of 95 %
TFA, H2O and TIS, and the final crude TAMRA-LPETGG was purified by reversed-phase
HPLC on a C18 column using a 10 – 70 % Buffer B (H2O, Acetonitrile and 0.05% TFA)
gradient over 15 mins. The fractions were analyzed by LC/MS and the desired fractions were
pooled together and lyophilized to dryness. We also designed a 25-mer peptide,
MSYYHHHHHHDYDIPTCENLPETGG (or H6-LPETGG peptide, hereafter) that was labeled
with fluorescein (or CruzQuencher) at the N-terminus using the same protocol described for
labeling with TAMRA. For labeling of the H6-LPETGG peptide at the internal cysteine residue,
the lyophilized peptide was reconstituted into water and the pH adjusted to around 8. Three
molar equivalents of fluorescein (in DMSO) was added to 5mg of peptide in 50 mM Tris-HCl,
pH 7.3 and 150 mM NaCl, and incubated at room temperature overnight. The labeled peptide
was purified, analyzed and lyophilized using the method described above. Measurement of the
absorbance of the peptide and fluorophore at 280 nm (A280 and Amax, respectively) and their
molar extinction coefficients (εprotein and εmax, respectively), allowed us to calculate the peptide
concentration and degree of labeling using equation 1 below;

𝐷𝑂𝐿 =

𝐴𝑚𝑎𝑥 ∙ 𝜀𝑝𝑒𝑝𝑡𝑖𝑑𝑒
(𝐴280 − 𝐴𝑚𝑎𝑥 ∙ 𝐶𝐹280 ) ∙ 𝜀𝑚𝑎𝑥
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The correction factor (CF) is included in this equation to account for the absorption of
fluorophore at 280 nm and equals the A280 of the dye divided by the Amax of the dye.
TAMRA-LPETGG labeling of Gly-EGFR, Gly2-EGFR and Gly4-EGFR
0.5 mM of TAMRA-LPETGG was mixed with 25 M of either Gly-EGFR, Gly2-EGFR or Gly4EGFR and 1 M SrtA 5M in a buffer containing 50 mM Tris-HCl pH 7.5, 150 mM NaCl, and 10
mM CaCl2. The reaction was incubated at 4 C with shaking and aliquots taken at 1 min, 5 mins,
15 mins, 30 mins and 1 hr. These, together with their unlabeled counterparts, were boiled in
SDS-gel loading buffer for 2 mins and analyzed by SDS-PAGE.
Quenching of sortase activity by EDTA and EGTA
1.5 M of SrtA 5M was added to a reaction containing 6.25 M of o-aminobenzoyl-LPETG-2,4dinitrophenyl in 20 mM HEPES, pH 7.5, 10mM CaCl2, in the presence and absence of 10 and 20
M of EDTA or EGTA. The samples were incubated at 37 C for 1 hr and analyzed in a
spectrophotometer using 340 nm for excitation and recording the emission maximum at 420 nm.
Sortase-mediated labeling and purification of EGFR kinase domain
In our newly developed strategy for labeling EGFR kinase domain with a fluorophore using
sortase (Figure 3.1) , 0.5 mM of CruzQuencher-labeled H6-LPETGG peptide was mixed with 25
M of Gly-EGFR and 1 M SrtA 5M in a buffer containing 50 mM Tris-HCl pH 7.5, 150 mM
NaCl, and 10 mM CaCl2. The reaction was incubated at 4 C for 30 mins and quenched with 10
mM EDTA. This was loaded onto a Superdex 75 10/30 GL column (GE Healthcare Life
Sciences, Pittsburg, PA) and pooled fractions containing the EGFR kinase domain was incubated
with 200 l of Nickel NTA beads at 4 C for 30 mins. CruzQuencher-labeled EGFR was eluted
with 125 mM imidazole, buffer exchanged into Buffer A (25 mM Tris-HCl pH 7.5, 150 mM
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NaCl, 1 mM DTT) and concentrated to ~ 1 mg/ml. Aliquots were taken at each step of the
process and analyzed by SDS-PAGE. We determined the concentration and degree of labeling of
the CruzQuencher-labeled EGFR using equation 1, where peptide is replaced with protein in the
equation.

Figure 3.1. Schematic representation of N-terminal labeling of TEV-cleavable proteins
using sortase. Green circle at the N-terminus of peptide indicates the fluorophore or any other
desired moiety. Affinity tag used in here was 6x-His. However, this tag can be varied and the
purification process can be made more stringent by using two different affinity tags. As noted in
the text, the TEV recognition motif used must be ENLYFQG rather than ENLYFQS.
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Sortase-mediated labeling and purification of MSP1E3D1 protein
MSP1E3D1 protein was treated with TEV protease to generate Gly- MSP1E3D1. 0.5 mM of
fluorescein-labeled H6-LPETGG peptide was mixed with 25 M of Gly- MSP1E3D1 and 1 M
SrtA 5M in a buffer containing 50 mM Tris-HCl pH 7.5, 150 mM NaCl, and 10 mM CaCl2. The
reaction was incubated at 4 C for 30 mins and quenched with 10 mM EDTA. This was loaded
onto a Superdex 75 10/30 GL column (GE Healthcare Life Sciences, Pittsburg, PA) and pooled
fractions containing the MSP1E3D1 protein were incubated with 200 l of Nickel NTA beads at
4 C for 30 mins. Fluorescein-labeled MSP1E3D1 was eluted with 125 mM imidazole, buffer
exchanged into Buffer A (25 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM DTT) and
concentrated to ~ 1 mg/ml. Aliquots were taken at each step of the process and analyzed by SDSPAGE. We determined the concentration and degree of labeling of the fluorescein-labeled
MSP1E3D1 using equation 1, where peptide is replaced with protein in the equation.
Kinase activity of labeled EGFR kinase domain
The protocol used to measure the kinase activities of labeled EGFR kinase domains, both in
solution and on Nickel liposomes (to induce dimerization) have been described in Ref. 36.
Wildtype or fluorophore-labeled EGFR kinase domain were incubated in 20 mM Tris, pH 7.5, 10
mM MgCl2, 100 M Na3VO4, 2 mM DTT, 100 M ATP, 1 Ci of [- 32P] ATP, 60 mM NaCl,
5% glycerol in 25-l total reaction volume. The reaction was initiated by the addition of 1.25 M
kinase, incubated at 30 C for 6 mins and quenched with EDTA. 100 g of avidin was added to
the samples and transferred to centrifugal filtration units with 30,000 molecular weight cutoff
(Millipore). The samples were washed four times with 0.5 M sodium phosphate, 0.5 M NaCl, pH
8.5 and the retained 32P measured by scintillation counting. The kinase activity on liposomes was
measured by incubating the wildtype and fluorophore-labeled EGFR kinase domains with nickel
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liposomes on ice for 15 mins before initiating the reaction. Total lipid concentration was 0.5
mg/ml.
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3.5 RESULTS
Expression and TEV protease cleavage of EGFR kinase domain constructs
The Sf9 insect cell baculovirus system was used to express all EGFR kinase domain (residues
constructs. Our two-step purification strategy (Nickel NTA chromatography and Gel filtration)
resulted in >95% purity and ~60% yield. Following overnight incubation with TEV protease, we
performed a reverse Nickel NTA purification by binding the TEV protease and uncleaved EGFR
kinase domain to the Nickel beads. The flow through containing the TEV protease-cleaved
EGFR kinase domain was concentrated, resulting in >95% purity and ~30% yield (figure 3.2).
Time-dependent incubation of EGFR kinase domain with TEV protease allowed the shortening
of the incubation period from 16hours to less than 8 hours and still preserves the activity of the
EGFR kinase.

Figure 3.2. Coomassie-stained SDS-PAGE gel of EGFR kinase domain purification and
TEV protease cleavage.
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Expression and enzymatic activity of Sortase A 5M (with no His-tag)
Bacterial expression of Sortase A 5M (with and without His-tag) produced milligram amounts of
the proteins, which were purified using a one-step Nickel NTA chromatography. The protein
yield was 75% while SDS-PAGE analysis showed a >95% purity of the TEV protease-cleaved
Sortase A 5M (figure 3.3). Enzymatic activity assays using o-aminobenzoyl-LPETG-2,4dinitrophenyl as a substrate showed that Sortase A 5M (without a His-tag) had comparable
sortase activity to the wildtype Sortase A 5M, as showed in Figure 3.4.

Figure 3.3. Coomassie-stained SDS-PAGE gel of Sortase A 5M (without a His-tag)
purification and TEV protease cleavage.
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Figure 3.4. Sortase activity of 6x-His SrtA 5M and TEV-cleaved SrtA 5M

One N-terminal glycine is required for sortase-mediated labeling of EGFR KD
We tested whether additional N-terminal glycines (Gly2-EGFR and Gly4-EGFR) are better
substrates in the sortase-mediated reaction. Our results using the TAMRA-labeled LPETGG
peptide showed that the labeling of Gly-EGFR, Gly2-EGFR, and Gly4-EGFR were very similar
(figure 3.5). The addition of several N-terminal glycine residues had no effect on the efficiency
of the reaction and all future experiments utilized one N-terminal glycine for the sortasemediated labeling reaction
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Figure 3.5. Comparison of labeling of Gly-EGFR, Gly2-EGFR and Gly4-EGFR using an
LPETG peptide substrate containing the TAMRA fluorophore.

Inhibition of sortase enzymatic activity by metal chelators
We tested the chelating effect of EDTA and EGTA at different concentrations of the metal
chelators. Our results showed that both chelators at 10 mM concentration were sufficient in
quenching the activity of sortase.
Fluorophore-labeled EGFR KD has comparable kinase activity to wildtype
Comparison of the kinase activity of a fluorophore-labeled EGFR kinase domain (Alexa568EGFR KD) shows similar fold of activation to the wildtype EGFR kinase domain (figure 3.6).
We have consistently achieved a 10-12 fold of kinase activation of the fluorophore-labeled
EGFR kinase domain on nickel liposomes, which is comparable to the activation of wildtype
EGFR kinase domain.
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Figure 3.6. Effect of fluorophore label on EGFR kinase domain activity and activation on
nickel liposomes

Affinity tagged peptide aids in post labeling purification of labeled EGFR KD and MSP
protein
N-terminal labeling of Gly-EGFR using sortase and a short peptide (that contains the fluorophore
and the sortase recognition motif) initially resulted in <60% modification of the protein with the
labeled peptide. This was due to the presence of unlabeled EGFR kinase domain (which differs
from the labeled EGFR kinase, in molecular weight terms by the presence of a fluorophore) and
could not be easily removed by gel filtration. We hypothesized that the addition of an affinity tag
to the LPETG sortase substrate would enhance the purification of only the labeled protein. We
designed a peptide that had a 6× histidine tag (for purification of labeled EGFR from unlabeled
EGFR), a cysteine residue for maleimide labeling (we also utilized the NH2-amino group of the
peptide for labeling with NHS-succinimidyl esters) and an LPETGG motif at the C-terminus.
Labeling of Gly-EGFR with the H6-LPETGG peptide results in the regeneration of the sequence
N-terminal to the EGFR that was cleaved off during TEV protease digestion (albeit subtle
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mutations at the C-terminus of the peptide, ENLPETG instead of the original ENLYFQG).
Figure 3.7 shows the use of this strategy to site specifically label TEV protease-cleaved EGFR
KD with the H6-LPETGG peptide labeled with a quencher (CruzQuencherTM1 Maleimide). Our
protein recovery from labeling 300 μg of EGFR was 140 μg, resulting in ∼50% protein yield.
Using equation 1 above, we have consistently achieved >0.95 moles of dye per mole of protein
in our purified labeled EGFR kinase domain.

Figure 3.7. Coomassie-stained gel showing the labeling and purification of EGFR kinase
domain using an LPETG peptide substrate containing CruzQuencher maleimide. Lanes; 1Unlabeled EGFR KD, 2- Reaction mix after 30 mins, 3- Fraction from Gel filtration, 4- Eluted
protein from Ni-NTA beads, 5- Final concentrated labeled protein
We also used this labeling and purification strategy to modify MSP1E3D1 at the N-terminus
using a fluorescein-labeled peptide. As shown in figure 3.8, we achieve >95% purity after
purification and the fluorescent image confirms the presence of the fluorophore on the protein.
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Figure 3.8. Coomassie and fluorescent gels showing the labeling and purification of MSP
protein using the H6-LPETGG peptide substrate containing fluorescein. Lanes; 1- Unlabeled
MSP, 2- Reaction mix after 30 mins, 3,4- Fractions from Gel filtration, 5- Eluted protein from
Ni-NTA beads, 6- Final concentrated labeled protein.

Figure 3.9. . Time course N-terminal labeling of EGFR KD using the H6-LPETGG peptide
substrate labeled with fluorescein at two different positions.
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3.6 DISCUSSION
We have demonstrated that TEV-cleaved recombinant proteins are good substrates for SrtA. The
use of TEV-cleaved proteins shows greater promise of practicality in biophysical and
biochemical applications, but there remained the challenge of sub-stoichiometric protein
modification due to back reaction and the reversible nature of sortase-mediated reactions.
Addition of an affinity tag to the peptide substrate enables the efficient purification of labeled
product, resulting in >95% purity. Although our strategy utilized the 6x histidine tag, which is a
commonly used affinity tag for protein purification, we propose that the protocol can be made
more stringent by employing two different affinity tags, one that is engineered into the protein of
interest (prior to TEV protease cleave) and the other that is part of the fluorophore-containing
peptide. The ability to site-specifically modify proteins with fluorophores to stoichiometric
proportions is highly desirable for downstream biophysical studies.
In our effort to obtain labeled EGFR kinase domains for biophysical studies, we tested different
strategies which included maleimide labeling of cysteine residues, lipoic acid ligase-mediated
click chemistry and sortase-mediated C-terminal labeling of EGFR kinase domain. The
challenges we faced were two-fold; the temperamental behavior of the EGFR kinase domain
where multiple rounds of cysteine-to-serine mutations compromised its enzymatic activity and
activation on nickel liposomes, and the tolerance of the kinase domain to reaction conditions.
While developing this robust labeling strategy, we realized that the sortase enzyme was still
active after loading the labeled products onto a size exclusion chromatography column. Since
this sortase A construct is calcium dependent, we demonstrated that molar equivalents of EDTA
or EGTA was sufficient to kill the activity of sortase. In addition, while a stretch of N-terminal
glycines can be used for the nucleophilic attack of the sortase-peptide intermediate, we have
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shown that one glycine residue was enough to allow this reaction to proceed. An interesting
discovery was the time needed for TEV protease cleavage of EGFR kinase domain. Standard
TEV protease protocols require overnight incubation (at least 16 hrs), which can be detrimental
to certain proteins. In our initial experiments, kinase activity assays of TEV-cleaved EGFR
kinase domains (incubated overnight) showed diminished enzymatic activities compared to the
wildtype EGFR. We have been able to optimize the conditions to minimize the incubation time
for TEV protease cleavage (currently 6 – 8 hrs is required to efficiently cleave the EGFR kinase
domain). However, we do experience ~50% loss in yield of the cleaved EGFR protein after the
reverse nickel purification process, a challenge we are working on to improve the yield. Lastly,
the H6-LPETGG peptide was carefully designed to enable the regeneration of the sequence
proximal to the EGFR kinase domain. Though not entirely understood, our data suggests that the
location of the fluorophore within this affinity peptide might enhance the fluorescent properties
of the labeled protein (Figure 3.9). We realized that the N-terminally labeled fluorophore peptide
exhibited greater fluorescence compared to the internal cysteine-labeled fluorophore peptide.
This might be attributed to the interaction of the fluorophore with the protein, depending on its
position and orientation.
The epidermal growth factor receptor, EGFR has been the archetypical protein for studying
receptor tyrosine kinases. EGFR and its orthologues (HER2, HER3 and HER4) have been known
to play significant roles in tumorigenesis. Our site-specific fluorophore-labeled EGFR kinase
domain offers a biological tool that can be used to answer mechanistic questions regarding
protein-lipid and protein-protein interactions by receptor tyrosine kinases. Since these proteins
are integrated into the membrane, the major challenge relates to careful selection of a
fluorophore that exhibits similar optical properties in the presence and absence of the lipid
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environment. Further, the development of the nanodisc technology by Sligar and colleagues has
allowed for biophysical studies of proteins in a native bilayer environment. We have
demonstrated the generality and applicability of this labeling strategy to other proteins by
labeling the membrane scaffold protein MSP1E3D1 using sortase. MSP constructs are used to
make nanodiscs and MSP1D1 has been site-specifically labeled using sortase and a fluoresceinlabeled depsipeptide (123). MSP1E3D1 in particular generates a 12.1 nm bilayer disc and has
been useful in solubilizing and studying membrane proteins in their functional forms (124). Our
fluorescein-labeled MSP1E3D1 broadens the utility and applicability of nanodiscs by providing
a toolbox to use bulk and single molecule fluorescent spectroscopy to study conformational
dynamics and macromolecular interactions between lipids and proteins.
In conclusion, the N-terminal amino group offers unique functional properties for site-specific
labeling of proteins. Our N-terminal labeling strategy provides a robust and straightforward
protocol for functionalizing TEV protease cleaved recombinant proteins via a sortase-mediated
reaction
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Chapter 4: Biophysical characterization of EGFR kinase domain
dimerization on lipid membranes
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4.2 ABSTRACT
The EGFR family of transmembrane receptor tyrosine kinases consists of EGFR, Her2, Her3 and
Her4 that are known to play significant roles in tumorigenesis. Their kinase domains form
asymmetric homo- and heterodimers necessary for activation, and leading to many downstream
signaling cascades. While these family members share a common architecture with high
sequence homology and structural similarity, the signaling potency of the different dimer pairs is
dependent on their dimerization partner. Though crystallographic studies have elucidated the
structures of EGFR homodimers, our current understanding of how the various heterodimers are
organized in three-dimensional space has been the result of cell biological and in vitro
biochemical assays. Our lab has shown that inhibition of Her3-Her2 heterodimers by Mig6 (an
endogenous protein) is significantly weaker than the other dimer pairs, with Mig6 having a lower
binding affinity to Her3. In addition, identification of mutations for all family members has
necessitated research into determining how interactions at the molecular level contribute to
activation. We hypothesized that structural differences at the dimer interface are one of the
factors controlling the functional characteristics of the different dimer pairs. We use a
combination of site-directed mutagenesis, in vitro kinase assays, biochemical and biophysical
approaches especially Fluorescence Resonance Energy transfer to directly measure EGFR kinase
domain dimerization on lipid surfaces. Our results using a dimerization-deficient control shows
that our current Nickel liposome system may not be a suitable system for measuring dimerization
of EGFR kinase domains on lipid membranes.
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4.3 INTRODUCTION
Abnormal signaling through the receptor tyrosine kinase of human EGFR family members
underlies many cancer tumors (10). This family of proteins includes EGFR, HER2, HER3 and
HER4 (3). All the members of the EGFR family share a common architecture: a large
extracellular domain, a single alpha helical transmembrane segment, an intracellular domain
containing the Tyr kinase domain (except HER3), and an unstructured C-terminal tail with
tyrosine autophosphorylation sites (4-7). With the exception of HER2, all three family members
are activated by ligand binding. Although HER3 has been regarded as a pseudokinase over the
past few years, recent studies have shown that its kinase domain contains a low
activity compared with the other three family members (4, 9). Ligand activation in the EGFR
family of proteins leads to receptor homo- and heterodimerization, and autophosphorylation of
tyrosine residues in the C- terminal region that provide docking sites for Src homology-2 or
other signaling molecules that contain phosphotyrosine-binding domains. This initiates a
cascade of signaling events that traverses the cytoplasm to communicate with the nucleus and the
cytoskeleton (11-14). Recent structural and mutational studies have shown that an allosteric
mechanism is necessary for activation by EGFR family dimers. This requires an interaction
between the C-lobe of one kinase monomer (activator kinase/donor monomer) and N-lobe of the
other monomer (receiver kinase/acceptor monomer). Alteration in the surface contact residues in
the N-lobe region in Her3 means that it can only serve as an activator in a heterodimeric pair (4).
Despite sequence and structural similarity, homo- and heterodimeric pairs of this family exhibit
distinct signaling potencies. Studies have shown that Her2 is the preferred signaling partner for
EGFR and HER3 with the HER2-HER3 heterodimers forming a potent signaling pair. Functional
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characterization has shown the dependence of the heterodimeric partners for efficient oncogenic
transformation (20). Using in vitro biochemical approaches, our lab has shown that an
endogenous protein, Mig6, inhibits HER2-HER3 heterodimers to a lesser extent compared with
its inhibition of other HER2 heterodimers (Figure 4.1). Mig6 binds to the distal surface of the Clobe of the kinase domain and inhibits dimerization (39). However, how molecular interactions
at these dimeric interfaces impact the function of EGFR signaling is not fully understood.
Whereas structural data can form the basis of the design of drugs to these receptors, effective
therapeutic interventions would necessitate the accurate measurement of binding affinities and
kinetic parameters inherent in protein-protein interactions in the EGFR family of kinases. We
propose a quantitative approach to measure EGFR family kinase domain dimerization. This
would provide direct experimental data regarding thermodynamic and kinetic parameters that
govern EGFR dimerization. We will focus mainly on the kinase domain as our starting point
since 1) it serves as a link between the extracellular domain and the C-terminal tail for activation
and phosphorylation of other proteins, and 2) it gives us a baseline of significant experimental
data that would enable us make predictions about how addition of other regions (such as the
juxtamembrane domain and C-terminal tail) may impact dimerization and guide us to test these
regions. Determination of these parameters with regards to how the kinase domain mutants
interact with other family members will inform the field on the mechanism involved in the
altered activation and signaling differences exhibited by these mutants.
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Figure 4.1 Mig6 inhibition of HER2 heterodimers
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4.4 METHODS
Plasmids
DNA encoding residues 696–1022 of the human epidermal growth factor receptor was cloned
into pFAST BAC HT (Invitrogen) using the NcoI and HindIII restriction sites. This EGFR
wildtype kinase domain construct contains an N-terminal 6-His tag, a linker, and a TEV protease
cleavage site (MSYYHHHHHHDY DIPTTENLYFQGAM). Multisequence alignment of the
EGFR family of proteins shows that their kinase domains contain seven cysteine residues, five of
which are conserved (figure 4.2). The six cysteines in the EGFR kinase domain were mutated to
serines, either individually or in combination. The nomenclature of the six cysteines was made to
reflect conservative cysteines in our prior fluorophore labeling studies of the HER4 kinase
domain. Table 4.1 and figure 4.3 provides the nomenclature and position of the cysteines in the
structure of the kinase domain, respectively. Site-directed mutagenesis of cysteines was done
using the QuikChange kit (Stratagene). Each construct was verified by DNA sequence analysis.
We also used an in-fusion method to insert a DNA sequence at the C-terminus of the EGFR
kinase domain, the expression of which generates an EGFR kinase domain containing an LPETG
motif at the C-terminus. This insertion was also confirmed by DNA sequence analysis.
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Figure 4.2. Multisequence alignment of the kinase domains of EGFR family members

Cysteine
residue
Cysteine-775
Cysteine-781
Cysteine-797
Cysteine-818
Cysteine-939
Cysteine-950

Nomenclature

Notes

C0
C1
C2
C3
C5
C6

NA
Close proximity to dimer interface
Reacts irreversibly with therapeutic inhibitors
NA
NA
NA

Table 4.1. Nomenclature of cysteine residues in the EGFR kinase domain
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Figure 4.3. Cysteine residues in the kinase domain of wildtype EGFR. This figure was
generated using PYMOL and the 2GS2 EGFR crystal structure

Expression and purification of EGFR KD Cysteine-to-Serine mutants
We expressed and purified the EGFR kinase domain cysteine-to-serine mutants using a protein
expression protocol described previously (4, 36). Recombinant bacmids (Bac-to-Bac expression
system, Gibco BRL) were transfected into Spodoptera frugiperda Sf9 cells to produce
recombinant baculovirus, which were used to infect Sf9 cells grown at 27 °C and 120 rpm in
IPL-41 medium (Invitrogen) supplemented with 10% bovine calf serum supplemented
(Hyclone), yeastolate extract (Invitrogen), penicillin, streptomycin, and Pluronic F-68. Cultures
at a density of 1 x 106 cells/ml were infected at 1 MOI and cells were harvested 48 – 72hours
post infection by centrifugation at 6000 rpm and resuspended in Buffer A (25 mM Tris-HCl, pH
80

8, 300 mM NaCl, 10 mM imidazole, 5% glycerol, 1 mM DTT) supplemented with
phenylmethylsulfonyl fluoride, benzamidine, DNase, and protease inhibitor mixture tablets
lacking EDTA (Roche). The cells were homogenized using a probe sonicator and the lysate was
centrifuged at 20000 rpm for 45 mins. 0.5 - 0.75 ml of Ni-NTA beads (Qiagen) were added to
the supernatants and incubated on a rotator for 1 h at 4 °C. The beads were poured into a 10-ml
disposable column (Bio-Rad) and the flow-through collected. The column was washed with 10
column volumes of Buffer A + 20 mM imidazole, and the proteins were eluted with Buffer A +
50–125 mM imidazole. The eluted fractions were further purified by gel filtration
chromatography on a Superdex 200 GL 10/300 column (GE Healthcare) using 20 mM Tris-HCl,
pH 8, 150 mM NaCl, 1 mM DTT buffer.
LplA ligase/Click Chemistry conditions on EGFR KD activity
We used an already published protocol to determine the effect of click chemistry conditions on
the enzymatic activity of EGFR kinase domain (125, 126). 50 M of EGFR kinase domain was
mixed with 100 M CuSO4, 0.5 mM Tris(3-hydroxypropyltriazolyl-methyl)amine, 5 mM
Sodium ascorbate, 5 mM Aminoguanidine in buffer containing 100 mM potassium phosphate,
pH 7.0 and 100 mM NaCl in a 2ml Eppendorf tube. The tube was closed and attached to a
rotisserie and the reaction allowed to proceed for 1 hr. An aliquot of the final reaction was taken
and the kinase activity determined, along with positive and negative controls. Positive control
included the untreated wildtype EGFR kinase domain while negative controls included reactions
that had one or more components omitted.
Design and fluorophore-labeling of oligoglycine peptides for C-terminal labeling
We used solid-phase synthesis to make two different oligoglycine peptides; GGGK and
GGGCGGAWSHPQFEK. The eight-amino acid sequence, WSHPQFEK is a strep tag and
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interacts with a specially engineered streptavidin construct called strep tactin. Following
cleavage from the resin, the final crude oligoglycine peptides were purified by reversed-phase
HPLC on a C18 column using a 10 – 70 % Buffer B (H2O, Acetonitrile and 0.05% TFA)
gradient over 15 mins. The fractions were analyzed by LC/MS and the desired fractions were
pooled together and lyophilized to dryness. The lyophilized peptides were reconstituted into
water and the pH adjusted to around 8. Three molar equivalents of fluorescein or QSY7
maleimide (in DMSO) were added to 5 mg of peptide in 50 mM Tris-HCl, pH 7.3 and 150 mM
NaCl, and incubated at room temperature overnight. The labeled peptides were purified,
analyzed and lyophilized using the same method described above. Measurement of the
absorbance of the peptide and fluorophore at 280 nm (A280 and Amax, respectively) and their
molar extinction coefficients (εprotein and εmax, respectively), allowed us to calculate the peptide
concentration and degree of labeling using equation 1 below;

𝐷𝑂𝐿 =

𝐴𝑚𝑎𝑥 ∙ 𝜀𝑝𝑒𝑝𝑡𝑖𝑑𝑒
(𝐴280 − 𝐴𝑚𝑎𝑥 ∙ 𝐶𝐹280 ) ∙ 𝜀𝑚𝑎𝑥

The correction factor (CF) is included in this equation to account for the absorption of
fluorophore at 280 nm and equals the A280 of the dye divided by the Amax of the dye.
C-terminal fluorophore labeling of EGFR KD using Fluorescein-labeled GGGK peptide
A solution containing 25 M of EGFR kinase domain (containing the LPETG sortase
recognition motif at the C-terminus), 6 M sortase and 0.5 mM fluorescein-labeled GGGK
peptide was mixed together in a buffer containing 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10
mM CaCl2. The reaction was incubated at 4 C for 30 mins in the dark. This was loaded onto a
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Superdex 75 GL 10/300 column (GE Healthcare) using 20 mM Tris-HCl, pH 8, 150 mM NaCl, 1
mM DTT buffer. Fractions containing EGFR kinase domain were pooled together, concentrated
and snap-frozen at -80 C. Aliquots were taken at this step and analyzed by SDS-PAGE followed
by Coomassie staining. The controls included were: EGFR kinase domain (containing the
LPETG sortase recognition motif at the C-terminus) only, sortase only, fluorescein-labeled
GGGK peptide only, EGFR kinase domain (containing the LPETG sortase recognition motif at
the C-terminus) and sortase, EGFR kinase domain (containing the LPETG sortase recognition
motif at the C-terminus) and fluorescein-labeled GGGK peptide, sortase and fluorescein-labeled
GGGK peptide.
C-terminal fluorophore labeling of EGFR KD using Fluorescein and QSY7-labeled
GGGCGGAWSHPQFEK peptide
A solution containing 25 M of EGFR kinase domain (containing the LPETG sortase
recognition motif at the C-terminus), 6 M sortase and 0.5 mM fluorescein-labeled
GGGCGGAWSHPQFEK peptide was mixed together in a buffer containing 50 mM Tris-HCl
pH 7.5, 150 mM NaCl, 10 mM CaCl2. The reaction was incubated at 4 C for 30 mins in the
dark. This was quenched with 10 mM EDTA and loaded onto a Superdex 75 GL 10/300 column
(GE Healthcare) using 20 mM Tris-HCl, pH 8, 150 mM NaCl, 1 mM DTT buffer. Pooled
fractions containing the EGFR kinase domain was incubated with 100 l of strep tactin II beads
at 4 C for 30 mins. Fluorescein-labeled EGFR was eluted with 2.5 mM desthiobiotin, buffer
exchanged into Buffer A (25 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM DTT) and
concentrated to ~ 1 mg/ml. Aliquots were taken at each step of the process and analyzed by SDSPAGE. We determined the concentration and degree of labeling of the fluorescein-labeled EGFR
using equation 1, where peptide is replaced with protein in the equation.
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Design and fluorophore-labeling of peptides for N-terminal labeling
We

designed,

synthesized,

and

purified

a

25-mer

peptide,

MSYYHHHHHHDYDIPTCENLPETGG (or H6-LPETGG peptide). The internal cysteine was
labeled with different maleimide fluorophores, depending on the downstream application. The
maleimide fluorophores used were Alexa350, Alexa488, Alexa568 and fluorescein. Three molar
equivalents of fluorophore were made to react with one molar equivalent of peptide at room
temperature overnight. The resulting labeled peptides were purified, analyzed and lyophilized
using the method already described. The degree of labeling was calculated using equation 1.
N-terminal fluorophore labeling of EGFR KD
The method used to site-specifically fluorophore label the EGFR kinase domains at the Nterminus using a sortase-mediated reaction has been described exhaustively in chapter 3.
LPETGG peptides labeled with any of the four fluorophores (Alexa350, Alexa488, Alexa568 or
fluorescein) was incubated with Gly-EGFR and sortase in a buffer containing 50 mM Tris-HCl
pH 7.5, 150 mM NaCl, and 10 mM CaCl2 under similar reaction conditions and reagent molar
equivalents, as described already. Fluorophore-labeled EGFR kinase domains were concentrated
to ~1 mg/ml and the degree of labeling calculated using equation 1.
Kinase activity of EGFR KD mutants and fluorophore-labeled EGFR KD
The protocol used to measure the kinase activities of labeled EGFR KDs, both in solution and on
Nickel liposomes (to induce dimerization) have been described in Ref 36. Wildtype or
fluorophore-labeled EGFR KDs were incubated in 20 mM Tris, pH 7.5, 10 mM MgCl2, 100 M
Na3VO4, 2 mM DTT, 100 M ATP, 1 Ci of [- 32P] ATP, 60 mM NaCl, 5% glycerol in 25-l
total reaction volume. The reaction was initiated by the addition of 1.25 M kinase, incubated at
30 C for 6 mins and quenched with EDTA. 100 g of avidin was added to the samples and
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transferred to centrifugal filtration units with 30,000 molecular weight cutoff (Millipore). The
samples were washed four times with 0.5 M sodium phosphate, 0.5 M NaCl, pH 8.5 and the
retained 32P measured by scintillation counting. The kinase activity on liposomes were measured
by incubating the wildtype and fluorophore-labeled EGFR KDs on ice for 15 mins before
initiating the reaction. Total lipid concentration was 0.5 mg/ml. Samples tested included EGFR
KD wildtype, Gly-EGFR KD, Fluorescein-labeled EGFR KD, Alexa488-labeled EGFR KD,
Alexa568-labeled EGFR KD, CruzQuencher-labeled EGFR KD, EGFR KD (with an LPETG
motif at the C-terminus), and EGFR KD labeled with either GGGK-fluorescein,
GGGCGGAWSHPQFEK-fluorescein or GGGCGGAWSHPQFEK-QSY7 at the C-terminus.
FRET assay using Alexa488-labeled-EGFR and Alexa568-labeled EGFR
1M Alexa488-labeled EGFR KD was mixed with 1M or 2M of Alexa568-labeled EGFR KD
in a buffer containing 20 mM Tris-HCl, pH 8, 150 mM NaCl, 1 mM DTT or Nickel liposomes.
The total volume of the mixture was 22l. This was incubated on ice for 20mins, aliquoted into
384 corning plate wells and placed in an Infinite M200 Microplate reader. The mixture was
excited at 490nm and fluorescent measurements taken over a wavelength range between 520nm
and 620nm. Controls included Alexa488-labeled EGFR KD(V-R dimerization-deficient mutant)
in buffer or on nickel liposomes, Alexa568-labeled EGFR KD(V-R dimerization-deficient
mutant) in buffer or on nickel liposomes, Alexa488-labeled H6-LPETGG peptide in buffer or on
nickel liposomes, Alexa568-labeled H6-LPETGG peptide in buffer or on nickel liposomes and
nickel liposomes only.
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4.5 RESULTS
EGFR kinase domain Cysteine mutants have diminished kinase activity
The enzymatic kinase activity of EGFR kinase domain was to determine the structural and
functional integrity of the cys-ser mutants. We measured the phosphorylation of a biotinylated
degenerate peptide by the cys-ser mutants. Compared to wildtype EGFR kinase domain, four of
the singly mutated cys-ser constructs showed similar kinase activity. However, mutations at two
key cysteine residues (C1 for Cys781 and C2 for Cys797) resulted in abrogation of the kinase
activity. We made triple, quadruple and quintuple constructs that contained those cys-ser mutants
that showed appreciable kinase activity. We also tested mutating C1 to alanine and C2 to
aspartate and asparagine. Our data suggests that combination of these cysteine mutations in the
quintuple mutant resulted in very low kinase activity compared to the wildtype (Figures 4.4 to
4.11)

Figure 4.4. Effect of single cysteine mutation (EGFR C0, C1 and C2) on kinase activity and
activation on liposomes. Cysteines at respective residues were mutated to serines.
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Figure 4.5. Effect of single cysteine mutation (EGFR C3, C5 and C6) on kinase activity and
activation on liposomes. Cysteines at respective residues were mutated to serines.

Figure 4.6. Effect of triple (C0C5C3) and quadruple (C0C5C3C2) cysteine mutations on
kinase activity and activation on liposomes. Cysteines at respective residues were mutated
to serines.
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Figure 4.7. Effect of single (C1, C-A) and quadruple (C0C5C3C2) cysteine mutations on
kinase activity and activation on liposomes. In the quadruple mutant, all cysteines have
been mutated to serines, while in the single mutant, cysteine at position C1 has been
mutated to alanine.

Figure 4.8. Effect of cysteine mutation at the C2 position in the quadruple mutant
(C0C5C3C2) on kinase activity and activation on liposomes. Apart from the C2 positions
that have been mutated to alanine, aspartate or asparagine, all other cysteines at the other
positions have been mutated to serine.
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Figure 4.9. Effect of cysteine mutation at the C2 position in the quadruple mutant
(C0C5C3C2) on kinase activity and activation on liposomes. Comparing cysteine to serine
or cysteine to asparagine mutation at the C2 position in the quadruple mutant.

Figure 4.10. Effect of cysteine mutation at the C1 and C2 positions in two quadruple
mutants (C0C5C3C2 and C0C5C3C1) on kinase activity and activation on liposomes. In
the C0C5C3C1 mutant, the C1 has been mutated to alanine while all other cysteines are
mutated to serine. In the C0C5C3C2 mutants, C2 is either mutated to aspartate or
asparagine while the three other cysteines are mutated to serines.
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Figure 4.11. Effect of EGFR kinase domain pentamutant (C0C5C3C2C1) on kinase activity
and activation on liposomes. While the other three cysteines (C0C5C3) have been mutated
to serines, C1 is mutated to alanine while C2 is mutated to asparagine.

LplA ligase/Click chemistry conditions inhibit EGFR KD activity
We subjected the EGFR kinase domain to conditions that were required for click chemistry using
LplA ligase. We also excluded some components of the reaction mixture to determine the effect
of those components on the activity of EGFR KD. After 60 minutes of reaction, we measured the
kinase activity of EGFR KD with and without the click chemistry components. Figure 4.12
shows that the addition of CuSO4, sodium ascorbate and THPTA results in the loss of kinase
activity.
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Figure 4.12. Kinase activity of EGFR kinase domain with LplA ligase and CuAAC
conditions. EGFR WT, EGFR wildtype , EGFR WT click, EGFR wildtype mixed with
CuSO4, Tris(3-hydroxypropyltriazolyl-methyl)amine, Sodium ascorbate, Aminoguanidine
in buffer, EGFR w/o copper, EGFR wildtype mixed with, Tris(3-hydroxypropyltriazolylmethyl)amine, Sodium ascorbate, Aminoguanidine in buffer, EGFR w/o AG, EGFR
wildtype mixed with CuSO4, Tris(3-hydroxypropyltriazolyl-methyl)amine, Sodium
ascorbate in buffer.

C-terminal fluorophore-labeled EGFR KD has low kinase activation
Following successful elution of the labeled EGFR-LPETG with fluorescein-labeled
GGGCGGAWSHPQFEK peptide, our calculations resulted in >95% purity after the postlabeling purification. We obtained similar results when EGFR-LPETG was labeled with the
QSY-labeled GGGCGGAWSHPQFEK peptide. We also compared the kinase activity and
activation on nickel liposomes of EGFR KD WT to the labeled and unlabeled EGFR-LPETG.
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The results show a diminished kinase activity and activation of the EGFR-LPETG (and
fluorescein-labeled and QSY-labeled EGFR) as compared to wildtype (4.13)

Figure 4.13. Effect of EGFR kinase domain C-terminal modifications on kinase activity and
activation on liposomes. Samples; EGFR WT, EGFR wildtype, EGFR-lpetg, EGFR
wildtype engineered with LPETG sortase recognition motif, FL-lpetg, EGFR wildtype
engineered with LPETG sortase recognition motif and labeled with fluorescein at the Cterminus, EGFR-GGGK, EGFR wildtype engineered with LPETG sortase recognition
motif and labeled with GGGK peptide, QSY-lpetg,

EGFR wildtype engineered with

LPETG sortase recognition motif and labeled with QSY quencher at the C-terminus.

N-terminal fluorophore-labeled EGFR KD has comparable kinase activity to wildtype
We designed and synthesized an affinity tag-containing peptide that was labeled with a
fluorophore. This was used to label a TEV protease cleaved EGFR KD (g-EGFR) that generates
a nucleophilic glycine necessary for the sortase reaction. For detailed results of the challenges,
drawbacks and breakthroughs involved in successful labeling of EGFR KD at the N-terminus
with a fluorophore, please refer to chapter 3. Initially, when we compared the kinase activities
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and activation of fluorescein-labeled EGFR to wildtype EGFR, the data showed that the labeled
EGFR kinase domains had comparatively lesser activity and lowered fold activation on nickel
liposomes. We subjected the wildtype EGFR KD to a mock TEV protease digestion (containing
no TEV protease), mock labeling (with no sortase) and subsequent purification with gel filtration
and Ni-NTA columns. Here, we show that mock-labeled EGFR KD has similar activity and fold
activation as labeled EGFR KD (Figure 4.14). We also show that fluorophore-labeled EGFR
kinase domain retains activity, following the shortening of the time required for TEV protease
cleavage and optimization of the purification steps (figure 4.15 and 4.16). These fluorophoremodified EGFR kinase domains had 95% purify after labeling and our calculations show that
there is a 1:1 fluorophore: protein ratio.

Figure 4.14. Effect of TEV protease cleavage, labeling and purification conditions on
EGFR kinase domain activity
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Figure 4.15. Effect of fluorophore labeling on EGFR kinase domain activity. EGFR kinase
domain was labeled with Alexa488 maleimide.

Figure 4.16. Effect of fluorophore labeling on EGFR kinase domain activity. EGFR kinase
domain was labeled with Alexa568 maleimide.
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Alexa488-EGFR interacts with Alexa568-EGFR when in close proximity
Following Nickel liposome incubation, the data shows a ~50% decrease in the donor (488EGFR) fluorescence and a ~35% increase in acceptor (568-EGFR) fluorescence as shown in
figure 4.17A. This fluorescence change was also reflected in the calculated FRET ratios (Table
4.2). Negative controls using dimerization-deficient EGFR KD (V924R mutant) labeled with the
Alexa FRET pairs also showed increased FRET ratios on liposomes as observed with wildtype
EGFR KD (Figure 4.17B). Lastly, peptide labeled with Alexa488 and Alexa568 produced data
that suggested an increase in the FRET ratio on liposomes as compared to solution conditions.
(figure 4.18)
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Figure 4.17. FRET measurements using Alexa488- and Alexa568-labeled EGFR kinase
domains. A. Measuring FRET using Alexa488- and Alexa568-labeled wildtype EGFR kinase
domain. B. Measuring FRET using Alexa488- and Alexa568-labeled dimerization-deficient
EGFR kinase domain mutant (Val924Arg).
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Figure 4.18. Effect of concentration of the fluorophore-labeled peptide alone on FRET
measurements

EGFR KD
EGFR KD (V924R)
MSYY peptide

FRET Ratio (Emission at 607nm/Emission at 530nm)
Buffer
Nickel Liposomes
0.09
0.24
0.1
0.20
0.05
0.1

Table 4.2. FRET ratios for EGFR kinase domain (and dimerization-deficient mutant) and
MSYY peptide. FRET ratio between 0.1 – 10 is considered a range that allows for
favorable efficiency calculations (127).
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4.6 DISCUSSION
The formation of an asymmetric dimer by EGFR (HER2, HER3 and HER4) kinase domains is
critical for activation and subsequent phosphorylation of their C-terminal tails. Notwithstanding,
mechanistic details regarding how these kinase domains dimerize is under investigation. Most
importantly, questions regarding binding affinities and kinetics of dimerization remain
unanswered. In this work, we attempted to develop a biological probe that can be used to directly
measure EGFR kinase domain dimerization on lipid surfaces. Our approach was to develop an
EGFR kinase domain construct that is site-specifically labeled with two fluorophores, either a
fluorescent donor-acceptor FRET pair or a fluorophore-quencher pair. Our enzymatic kinase
activity results with EGFR kinase domain cysteine mutants suggested that two key cysteine
residues (Cys781 and Cys797) were important for the structural and functional integrity of the
kinase. These two cysteines have been shown to be solvent accessible (128) while Cys797 have
been historically targeted by irreversible kinase inhibitors. The advent of chemoenzymatic
approaches allowed us to take advantage of a sortase-mediated approach to site-specifically
fluorophore-label the EGFR kinase domain at the C- and N-terminus. Unfortunately, C-terminal
labeling compromised the activation of the kinase. X-ray crystal structures show little to no
density of the distal region following the kinase domain core. From our analysis, we propose that
this region is close to the dimer interface and its alteration would have deleterious effects on the
structure and function of the kinase. The N-terminally labeled kinase domain provided an
excellent opportunity for use in developing quantitative approaches to measure dimerization. We
tested various donor-acceptor FRET pairs and a fluorophore-quenching system to develop this
dimerization assay. Our findings suggest that the fluorophores interact differently with the nickel
liposomes and this posed a huge challenge in establishing the requisite parameters for the assay.
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During the development of this assay with Alexa488 and Alexa568, we obtained appreciable
signal changes when EGFR kinase domains were incubated on liposomes. This result was
encouraging and provided preliminary evidence that the kinase domains incubated on nickel
liposomes were within a distance that allowed for transfer of energy. However, rigorous negative
control experiments with the dimerization-deficient mutant (Val924Arg) and the fluorophorelabeled peptide produced similar FRET results. The ability of the fluorophore-labeled peptide to
FRET (in the absence of EGFR kinase domain) shows that the assay might be measuring the
proximity of the peptides or proteins and not the transfer of energy. In fact, incubation on nickel
liposomes allows the concentration of the his-tagged EGFR KD, perhaps favoring
conformational changes that result in dimerization and subsequent activation. Although my
working concentration (protein) for my FRET assay is 1-2uM, this value translates to 1-2mM
local concentration of EGFR KD on liposomes (4). At such high concentrations, the fluorophore
pairs in the linker region are poised to FRET irrespective of the presence or absence of proteins.
In conclusion, this study presents a basis for further research to develop a biological probe to
measure EGFR kinase domain dimerization on lipid surfaces. While the nickel liposome/histagged kinase domain system presents challenges for directly measuring dimerization affinities,
our single-site fluorophore-labeled EGFR kinase domain can be useful in developing a different
optical-based assay to determine how these proteins interact. For instance, we have successfully
labeled the EGFR kinase domain containing the juxtamembrane segment with a FRET pair.
Since studies have shown that the JM can dimerize without the need of lipid membranes (46), we
can use this labeled JM construct and equilibrium studies (analytical ultracentrifugation) to
monitor EGFR kinase domain dimerization in solution.
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Chapter 5: Conclusion and Future Directions
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5.1 Conclusion and future perspectives
The biology of the EGFR family of receptor tyrosine kinases is intimately connected to the
structural organization of the different domains of these proteins. A deeper understanding of
these structures has aided the development of therapeutics that target different structural states of
both the extracellular and intracellular domains. However, the field has not made enough
advancement in characterizing the C-terminal tails and dissecting their unique structural features.
In this work, we provide experimental data that improves our basic understanding of the Cterminal tails in isolation. We also initiate experiments to build a platform that would enable the
quantitative measurement of kinase domain dimerization on lipid surfaces using site-specifically
fluorophore-labeled EGFR protein constructs.
We are the first to provide a comprehensive and detailed biophysical analysis of the C-terminal
tail of a receptor tyrosine kinase. In chapter 2, we use multiple biophysical approaches to
produce convincing experimental data that the EGFR and HER3 C-terminal tails are intrinsically
disordered. Since the discovery of EGFR and its involvement in several human cancers, the field
has made tremendous progress towards elucidating the structures of the various domains and
enhancing the development of therapeutics against EGFR and HER2 using these structures. Our
results provide stimulating impetus to investigate the dynamics of the C-terminal tails. Although
the C-terminal tails have comparable molecular weights to globular proteins, their apparent size
using the biophysical tools, are usually bigger than their globular counterparts. In fact, our data
using SAXS shows that the EGFR C-terminal tail assumes greater shape and size compared to
the compact, globular kinase domain. Such dynamic and flexible characteristics of the Cterminals are very important, given that they provide docking sites and interacting surfaces for
multiple proteins to bind.
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Several outstanding questions remain regarding the C-terminal tails. There is no structural or
biophysical information regarding the interaction of kinase domain and the C-terminal tail, prior
to activation. We have attempted to use Isothermal Calorimetry to determine the Kd of the tail
interacting with the kinase domain and have been unsuccessful. Given that these intrinsically
disordered regions have high on- and off rates, it is often a challenge to determine these
thermodynamic parameters. This is also compounded by the high molar ratios needed for this
interaction, and often requires the C-terminal tails to be in excess, a situation that can lead to
aggregation and difficulty in interpreting the data. Secondly, it is unknown how phosphorylation
affects the shape, size and conformation of the EGFR and HER3 C-terminals. In certain proteins,
it has been shown that there is a disorder-to-order transition following phosphorylation (129).
Since this is not a general phenomenon, it is important to determine how phosphorylation affects
the intrinsic disorder characteristics of these proteins. The challenge that remains is the
stoichiometric phosphorylation of these tails and effective separation of the fully phosphorylated
C-terminal tail from the partially and unphosphorylated species. We circumvented this by
expressing and purifying a phosphomimetic mutant (EGFR Y-E), where all the nine tyrosines
have been replaced with a glutamate residue. Preliminary SAXS measurements show that
wildtype EGFR C-terminal and the EGFR Y-E mutant have similar Rg values, and that there
might be no difference in size between the phosphorylated and unphosphorylated constructs.
Further biophysical studies need to be done to accurately measure the size and shape of the
phosphorylated species. A major criticism for using this strategy is that the Y-E mutant does not
fully represent the phosphorylated state of EGFR. Another important question that remains
unanswered is the significance of intrinsic disorder to the function of EGFR family of receptor
tyrosine kinases. In this realm, it might be necessary to combine these in vitro experiments with
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cell-based approaches to fully understand their importance. Since intrinsically disordered regions
are enriched in polar residues and have less hydrophobic residues, it will be important to create
mutants that are either less disordered or more disordered, and determine their effects in cellbased assays on signaling outputs.
Our study in chapter 3 provides a strategy that can be used to N-terminally label any recombinant
protein that contains a TEV cleavage site proximal to the protein core, using sortase. We
successfully use this sortase-mediated strategy to label two proteins, the EGFR kinase domain
and MSP1E3D1, a membrane scaffold protein. The genomic and post-genomic eras necessitate
the development of strategies for protein bioengineering and incorporation of a variety of
modalities to proteins for basic science research, biotherapeutics and biotechnological utility.
Protein modification approaches must be simple and robust, requiring shorter reactions times for
labeling. Such strategies should be amenable to functionalizing proteins with different handles at
any desired location with minimum structural and functional consequences. Most importantly,
protein labeling methods must be efficient, which enables their utility for quantitative and other
biophysical studies. A major challenge faced by labeling approaches pertains to the purity of the
labeled protein, and the related removal of unlabeled species. The N-terminal amino group offers
unique functional properties for site-specific labeling of proteins. Efficient labeling with Nhydroxysuccinimide esters requires controlled pH experiments to selectively modify the Nterminal amino group over lysine residues which is always challenging as a result of the
closeness in pKa of the α-amino group of the protein versus the ε-amino group of lysine. Sortase
fulfilled most of the requirements for chemoenzymatic modification of proteins, but still faced
the challenge of sub-stoichiometric labeling. However, post-labeling purification using an
affinity tag in the peptide substrate resulted in >95% purity of the labeled protein. Our strategy
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enables the use of labeled proteins for biophysical and biochemical studies as well as for
diagnostic purposes.
In chapter 4, we employed the single-site fluorophore labeled EGFR kinase domain to develop a
quantitative tool that can be used to measure dimerization on lipid surfaces. Our data suggests
that the assay we developed was measuring the proximity of the kinase domains, rather than
dimerization. This suggests that the nickel liposome system provides a platform that allows the
population of histidine-tagged proteins and that dimerization might be occurring on these
surfaces through a mechanism that is not completely understood, presumably altering the
conformation of the kinase domain. While most studies have shed light on the structural features
of the kinase domain and provided indirect measurement of the dimerization of kinase domains
on lipid membranes, there needs to be further investigation regarding the direct measurement of
dimerization and the determination of quantitative parameters that govern this. This would
provide us with a molecular understanding of how EGFR kinase domain dimerizes. Such
research provides signatures specific for each dimeric pair that would drive rational and
structure-based design of therapies that target these dimeric interfaces. In fact, the crystal
structure and chemical foot printing mass spectrometric analysis of the EGFR-HER3 and HER2HER3 dimers respectively (130,131), provides stimulating evidence for the field to initiate
investigations that would enhance the development of inhibitors that target the dimer interface of
homo- and heterodimers. Our lab and other groups have shown that certain cancer-associated
mutations are close to the dimer interface of the kinase domain. A robust dimerization assay
would enable us determine the effect of these activating mutations on dimerization.
Determination of these parameters with regard to how the kinase domain mutants interact with
other family members will inform the field on the mechanism involved in the altered activation
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and signaling differences exhibited by these mutants. It also provides a baseline of significant
experimental data that would enable us make predictions about how addition of other regions
(such as the juxtamembrane domain and C-terminal tail) may impact dimerization and guide us
to test these regions.
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